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Abstract 
HIV has emerged as one of the leading causes of childhood mortality and morbidity in sub 
Saharan Africa. But, the attention given to HIV-infected children in terms of providing ART had 
so far taken a second rank. This was because primary concern is about adults. The study had the 
objectives to assess the relationship of explanatory variables to survival time, estimate the 
survival duration and identify predictors that have significant impact on the survival status of 
HIV infected children who received antiretroviral treatment and care in Gondar University 
Hospital, Gondar, Ethiopia. The data used in the study was based on secondary data from 
hospital records of HIV infected children aged below 15 years who started ART between 2008 
and 2013 were included and followed until April 2015 in Gondar University Hospital, Gondar, 
Ethiopia. Kaplan-Meier survival curves and Log-Rank test are used to compare the survival 
experience of different category of children, and Multivariable Cox proportional model was 
fitted to identify factors affecting survival of children after initiation of ART. The estimation of 
the model parameters was done by partial maximum likelihood procedures. A total of 269 
records were included in the analysis. The median survival time was found to be 55 months. At 
the end of the follow up, 46 (17.1%) children died due to the disease, the remaining 223 (82.9%) 
were alive and loss to follow-up. The multivariate analysis of Cox regression model gives that 
age of a patient (for age < 1.5 years HR: 3.590 ; 95% CI: 1.439, 8.953; P = 0.006 and for age 1.5-
5 years HR: 2.632; 95% CI: 1.350, 5.130; P = 0.004), Baseline hemoglobin level (for 
hemoglobin level < 7g/dl HR: 6.286; 95% CI: 2.328, 16.973; P=0.000 and for hemoglobin level 
7-8.5g/dl HR: 5.592; 95% CI: 1.903, 16.436; P = 0.002), WHO clinical stage (For stage III HR: 
0.308 ; 95% CI: 0.150, 0.630; P = 0.001) and baseline CD4 count(HR: 0.180 ; 95% CI: 0.084, 
0.388; P = 0.000) are significant risk factors of survival of HIV infected children during the 92 
months of follow up. Therefore, special attention should be given to younger children in ART; 
patients with low CD4 cell count, patients with advanced WHO clinical staging (stage III and 
IV) and patients with low hemoglobin level are necessary in order to improve the survival of 
HIV infected children treated with ART.  
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CHAPTER ONE 
1. Introduction 
1.1. General Background of the Study 
Acquired immune deficiency syndrome (AIDS) is an infectious disease caused by the human       
immunodeficiency virus (HIV). The Human Immunodeficiency Virus (HIV) targets the immune 
system and weakens people's surveillance and defense systems against infections and some types 
of cancer. As the virus destroys and impairs the function of immune cells, infected individuals 
gradually become immune deficient. Immune function is typically measured by CD4 cell count. 
Immunodeficiency results in increased susceptibility to a wide range of infections and diseases 
that people with healthy immune systems can fight off.  
For three decades, HIV/AIDS has been overwhelming individuals and families with the disaster 
of untimely death and medical, financial and social burdens. The occurrence of AIDS epidemics 
are amongst the forefront public health challenges that the world has faced in recent past. 
Millions of people died of HIV infection during the last three decades. Globally, an estimated 35 
million (33.2 million–37.2 million) people were living with HIV in 2013 [1]. This number is 
rising as more people are living longer because of antiretroviral therapy, alongside the number of 
new HIV infections which, although declining, is still very high. There are 3.2 million [2.9 
million–3.5 million] children younger than 15 years living with HIV. The number of people who 
are newly infected with HIV is continuing to decline in most parts of the world.  
There were also 190,000 children died of AIDS-related illnesses during 2013, out of 1.5 million 
people overall. AIDS-related deaths have fallen by 19%, which represents the largest decline in 
the past 10 years. In sub-Saharan Africa, the number of AIDS-related deaths fell by 39% 
between 2005 and 2013. The region still accounted for 74% of all the people dying from AIDS-
related causes in 2013 [1]. 
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Mother-to-Child Transmission of HIV (MTCT) is the major source of HIV infection among 
children under the age of 15 years [2]. In 2013, 240 000 (210 000–280 000) children were newly 
infected with HIV. This is 58% lower than in 2002, the year with the highest number, when 580 
000 (540 000–640 000) children became newly infected with HIV. Providing access to 
antiretroviral medicines for pregnant women living with HIV has averted more than 900 000 new 
HIV infections among children since 2009. There are 2.9 million [2.6 million–3.2 million] 
children (aged 0–14) living with HIV in sub-Saharan Africa. Of the estimated 1.8 million people 
living with HIV 1.5 million were living in sub-Saharan Africa [3]. 
A decade ago, having AIDS was almost equivalent to a death sentence. Since 1996, with the 
introduction of combined antiretroviral treatment, AIDS has become chronic, manageable 
disease [5]. Currently in 2013, there are about 21 Food and Drug Administration (FDA) 
approved antiretroviral drugs (ARVs) in the world [6]. Antiretroviral therapy (ART) refers to the 
use of pharmacologic agents that have specific inhibitory effects on HIV replication. HIV can be 
suppressed by combination ART consisting of 3 or more ARV drugs. Three classes of ARVs are 
now available: Nucleoside reverse transcriptase inhibitors (NRTIs), Non-nucleoside reverse 
transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs). Entry and Fusion Inhibitors have 
also emerged as additional class of antiretroviral drugs [7]. 
Since 1995, antiretroviral therapy has averted 7.6 million deaths globally, including 4.8 million 
deaths in sub-Saharan Africa. ART does not cure HIV infection but controls viral replication 
within a person's body and allows an individual's immune system to strengthen and regain the 
capacity to fight off infections. Almost 12.9 million people were receiving antiretroviral therapy 
globally at the end of 2013. Approximately 11.7 million people living with HIV in low- and 
middle-income countries were receiving ART at the end of 2013, about 740 000 of those were 
children [8]. 
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1.2. Overview of the AIDS Epidemic in Ethiopia  
1.2.1. Current HIV/AIDS Profile 
In 2013 there were an estimated 793,700 (716,300-893,200) people living with HIV including 
200,300 (172,400 – 232,400) children according to the latest EPP/Spectrum modelling. As per 
the same modelling, the pediatrics HIV population in Ethiopia are mostly older children who 
were vertically infected in earlier years when the coverage and effectiveness of PMTCT in the 
country was low/MTCT rates high (in 2013 163,800 HIV positive children were aged 5-14 
years) [4].   
There were approximately 45,200 (36,500-55,200) AIDS related deaths in 2013 and about 
898,400 (770,700 – 1,048,500) AIDS orphans in the same year. HIV adult prevalence is 
estimated at 1.5% in 2011, the year in which the last Ethiopian Demographic Health Survey 
(DHS) was conducted [9].  
1.2.2. Antiretroviral Therapy in Ethiopia 
The scale up of free ART services has been one of the greatest achievements of the HIV program 
response over the last decade. ART program services have expanded on a large scale and have 
substantially decreased AIDS deaths and possibly contributed to the decline in HIV incidence 
since 2005. By the end of June 2013 the number of people ever enrolled in chronic care reached 
728,874 while the number ever started ART was 439,301 and 317,443 were currently receiving 
ART. Only 70.3% of individuals who ever started ART were currently on treatment indicating 
challenges in patients’ retention. Of the estimated 593,400 (540,100 – 668,300) adults living 
with HIV at the end of 2013 (EPP/Spectrum estimates 2014); 298,512 were on treatment (50%). 
In December 2013, Ethiopia adopted the new WHO integrated guidelines for treatment, in which 
adults with CD4 below 500, all pregnant women and all TB patients independent of CD4 count 
are eligible for treatment [10]. 
The estimated number of children live with HIV in Ethiopia in 2013 was around 200,300 
(172,400-232,400), only 18,931 (9.5%) received ART in 2013 [4]. This requires urgent attention 
to identify possible factors for low performance; increase efforts to identify children living with 
HIV in the community, especially in the older age ranges and develop strategic actions to 
improve coverage rates [10]. 
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1.2.3. The Purpose of Antiretroviral Therapy 
Although there are other factors that can help to keep a person with HIV infection well for many 
years, eventually it becomes necessary to take antiretroviral drugs in order to lengthen a person’s 
life. Antiretroviral drugs work directly on HIV and slow down its multiplication.  
This in turn slows down the loss of CD4 T-cells that the virus destroys, and thus slows down 
further damage to the immune system or even allows the immune system to recover to some 
extent. Controlling HIV infection and limiting damage to the immune system results in weight 
gain and improvement in general health, fewer opportunistic infections, less need for other 
medications and less time in hospital.  
Although antiretroviral therapy (or ART) is not a cure for AIDS, the purpose of anti-retroviral 
therapy is to:  
 Reduce the HIV viral load as much as possible, preferably to undetectable levels for as 
long as possible (Virological goal).  
 Assure that less damage will be inflicted on the immune system, so that the patient will 
experience an improvement in his/her immune functioning and to delay the onset of Aids 
(Immunological goal).  
 Enhance quality of life and reduce opportunistic infections (Therapeutic goal).  
 Reduce the impact of HIV transmission in the community (Epidemiological goal).  
 Reduce Mother-to-Child Transmission of HIV (MTCT) 
 Reduced HIV-related morbidity and mortality  
 Limitation of the likelihood of viral resistance to preserve future treatment option  
The primary goals of antiretroviral therapy are preventing HIV-related morbidity and improving 
quality of life, reducing mortality and improving survival, restore and preserve immunologic 
function, maximally suppress viral load, and ultimately preventing mother to child transmission 
[11].  
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Incomplete suppression of viral replication may be associated with continued immunologic and 
clinical deterioration and the evolution of additional resistance mutations. Patients who are 
unable to adhere strictly to complex medication regimens are those most likely to develop HIV-
drug resistance and to face limited future ART options [11]. 
Nowadays, antiretroviral treatments (ART) do not only aim to reduce morbidity and mortality 
caused by HIV infection and improving infected patients’ life. They also aim to prevent HIV 
infection [12]. Therefore, they have the interest of reaching universal access to ART goals (ART 
coverage superior or equal to 80% to those in need among infected patients) [13]. 
1.3. Statement of the Problem 
HIV/AIDS have been strong emotional effects on individuals and families with the disaster of 
untimely death and medical, financial and social burdens for the past three decades. The 
occurrence of AIDS epidemics are amongst the forefront public health challenges that the world 
has faced in recent past. Millions of people died of HIV infection during the last three decades. 
Globally, an estimated 35 million [33.2 million–37.2 million] people were living with HIV in 
2013. In sub-Saharan Africa, the number of AIDS-related deaths fell by 39% between 2005 and 
2013. The region still accounted for 74% of all the people dying from AIDS-related causes in 
2013 (1). There are 2.9 million [2.6 million–3.2 million] children (aged 0–14) living with HIV in 
sub-Saharan Africa. Of the estimated 1.8 million people living with HIV 1.5 million were living 
in this area. There were also 190,000 children died of AIDS-related illnesses during 2013, out of 
1.5 million people overall. (3) 
Ethiopia is one of the Sub-Saharan African countries hardly-hit by HIV/AIDS in all its 
manifestations. In 2013 there were an estimated 793,700 (716,300-893,200) people living with 
HIV including 200,300 (172,400 – 232,400) children according to the latest EPP/Spectrum 
modelling. As per the same modelling, the pediatric HIV population in Ethiopia are mostly older 
children who were vertically infected in earlier years when the coverage and effectiveness of 
PMTCT in the country was low/MTCT rates high (in 2013 163,800 HIV positive children were 
aged 5-14 years). There were approximately 45,200 (36,500-55,200) AIDS related deaths in 
2013 and about 898,400 (770,700 – 1,048,500) AIDS orphans in the same year [10].  
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Treatment of HIV- infected children with antiretroviral therapy (ART) leads to immune 
reconstitution as shown by increase in CD4 lymphocyte counts, decreased risk of opportunistic 
infection and improved survival [1 &2]. However, not all children have an optimal response to 
therapy. Viral load may not be well controlled because of poor drug adherence or other factors 
leading to the development of drug resistance. Some children, even when viral replication is 
controlled, have slow and incomplete recovery of immune function and remain at greater risk of 
AIDS associated events and death than those who show more rapid reconstitutions [3]. 
Moreover, children may die with undetectable viral load and adequate CD4 count recovery [4]. 
However, very little attention has been given to look into how factors other than ART drugs may 
influence the survival of HIV infected children. Therefore, this research work is undertaken 
against the above background and explores the factors that have strong association with the 
survival experience of HIV-infected children treated with ART in Gondar University Hospital. 
1.4. Objectives of the Study 
1.4.1. General Objective 
The main objective of the study is to assess the relationship of explanatory variables to survival 
time of HIV infected children after they started ART at Gondar University Hospital, Gondar, 
Ethiopia. 
1.4.2. Specific Objectives 
In the light of this major objective, the study intends  
 To estimate and compare the survival duration among the different groups of HIV 
infected children after initiation of ART. 
 To identify socio-economic, demographic and clinical predictor variables that affect the 
survival of children treated with ART. 
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1.5. Significance of the Study 
The outcome of this study would provide information about the risk factors or the most 
influential covariates that have significant impact on survival of children living with HIV/AIDS 
after initiation of ART in Gondar University Hospital. This work will also contribute to the 
literature on the determinant factors (influential covariates) for the survival of children living 
with HIV/AIDS after initiation of ART in Ethiopia. 
Furthermore, the study provides the following additional advantages: 
 The results are expected to give some knowledge about determinants and risk factors of 
the survival of HIV infected children treated with ART in Ethiopia.  
 It could be used as an input for other studies related to survival time of HIV infected 
children treated with ART. 
1.6. Limitations of the Study 
 The study is conducted based on secondary data which have some incomplete information. 
 The study was restricted to children under the age of 15 years, and results might not be 
applicable to adults older than 15 years of age 
 The study presumed that all deaths are caused by HIV infection. 
 Parts of information on individuals are missed because of censored observations. 
 The study is based on baseline values of the variables of interest. 
 As different literature pointed out, there are different factors that are assumed to have 
impacts on the survival of HIV patients like Virological variables. However, we did not get 
data on these variables to include in the analysis. This may make the study somewhat 
incomplete. 
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CHAPTER TWO 
2. Literature Review 
Epidemiological research has shown that there are critical differences in disease progression 
between children and adults. Largely due to the lower efficiency of a child’s immature immune 
system, children experience a much more rapid disease progression and a much shorter duration 
of each stage of HIV disease. In the absence of any intervention (like ARV), majority of 
perinatal HIV-infected children develop HIV-related symptoms by six months of age. There is 
limited data on clinical and biological indicators of disease progression in HIV-infected children 
in Africa [14 &16]. 
The natural course of HIV disease in the absence of treatment is often short and the majority of 
children are rapid progressors, with very few long-term survivors (15). Studies in resource-
constrained countries indicate that the risk of death in untreated HIV-infected infants is 45% at 
two years and 62% at five years. Delayed diagnosis of HIV infection, poor nutrition, and high 
levels of severe bacterial, respiratory and gastrointestinal tract infections are likely reasons for 
the higher early mortality [15, 16 &20]. 
In sub-Saharan Africa, progress has been made in the last few years toward expanding of 
preventive MTCT programs based on trial findings that have demonstrated the efficacy 
(biological effectiveness) of generally simpler and shorter ARV treatment and prophylactic 
regimens than those used in industrialized countries [17, 18 &19]. 
A study conducted on Long-Term Survival of HIV-Infected Children Receiving Antiretroviral 
Therapy in Thailand. A 5-Year Observational Cohort Study were done among 578 children 
received ART; of these, 111 (19.2%) were followed since birth. At start of ART (baseline), the 
median age was 6.7 years. Age <12 months, low CD4 cell percentage, and low weight-for-height 
z score at ART initiation were independently associated with mortality (P < .001). The 
probability of survival among infants aged <12 months at baseline was 84.3% at 1 year and 
76.7% at 5 years of ART, compared with 95.7% and 94.8%, respectively, among children aged 1 
year. Low CD4 cell percentage and wasting at baseline had a strong association with mortality 
among older children but weak or no association among infants.  
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Therefore, children who initiated ART as infants after meeting immunological and/or clinical 
criteria had a high risk of mortality which persisted beyond the first year of therapy. Among 
older children, those with severe wasting or low CD4 cell percentage at treatment initiation were 
at high risk of mortality during the first 6 months of therapy. These findings support the scale-up 
of early HIV diagnosis and immediate treatment in infants, before advanced disease progression 
in older children [21]. 
Another study was conducted to evaluate the rates and causes of hospitalization and mortality 
among HIV–infected children Thailand after receiving highly active antiretroviral therapy 
(HAART). One hundred ninety-two children were included. The mean age at HAART initiation 
was 7.6 years (range, 0.4–14.8 years). At baseline, the mean CD4 cell percentage (±SD) was 
5.2%±4.9%, and the mean plasma HIV RNA level (±SD) was log10 5.40.5 copies/ml. The 
mortality rate decreased from 5.7% in the first 24 weeks to 0%–0.6% in the subsequent 24-week 
intervals. Therefore, hospitalization and mortality rates significantly decreased among HIV-
infected children receiving HAART. Most hospitalizations and deaths occurred during the first 
24 weeks of HAART [22]. 
Another study from Cape Town on children known to be vertically infected with HIV has 
revealed that the risk of death was significantly associated with age less than 6 months and 
severity of disease at time of diagnosis. The median survival for all the children from time of 
diagnosis was 32 months. Infants diagnosed before 6 months of age had significantly shorter 
median survival (10 months) compared with 36 months for those diagnosed at 7-12 months of 
age. For the children over the age of 12 months the cumulative proportion surviving 48 months 
was 78%. Children with severe disease (category C) had a median survival of 21 months, 
significantly lower than that in category B (32 months). For the children in category A the 
cumulative proportion surviving at 48 months was 66% [23]. 
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A retrospective cohort study was designed to assess clinical factors associated with growth in 
HIV infected children on ART in Uganda. Descriptive and logistic regression analyses were 
conducted to identify covariates associated with risk of either stunting or being underweight. 
Children in World Health Organization clinical stages II, III, and IV at baseline were 1.5 times 
more likely to become underweight from that of Clinical stage I, but Initiation of ART resulted 
in improvement in mean standardized weight-for-age. Weight-for-age z-score improved 
significantly after initiation of ART. This pediatric population gained weight more rapidly than 
height after initiation of ART [24]. 
In a study to evaluate changes and risk factors for death among HIV-infected children in 
pediatric AIDS Clinical Trials Group 219/219c in US among 3553 HIV-infected children was 
followed up for a median of 5.3 years. The study shows that increased risk of death was 
significantly associated with low CD4, pneumonia and AIDS-defining illness at entry. Whereas, 
decreased risks of mortality were identified for children timely began highly active antiretroviral 
therapy [25]. 
A study was conducted on the impact of HIV on child mortality in rural Uganda. Clinical and 
laboratory data were collected every 3 months. Person years at risk were calculated from time of 
enrolment until earliest date of ART initiation, death or last visit. Cox regression was used to 
estimate hazard ratios (HR) for mortality. Eighty-nine HIV-infected and 206 HIV-exposed but 
uninfected children were enrolled, twenty-one children died. The mortality rate was six times 
higher in ART-naive HIV infected children than in HIV-exposed but uninfected children (HR = 
6.4, 95% CI = 2.4–16.6). Among HIV-infected children, mortality was highest in those aged <2 
years. Decreasing weight-for-age Z (WAZ) score was the strongest risk factor for mortality 
among HIV-infected children (HR for unit decrease in WAZ = 2.6, 95% CI = 1.6–4.1). Thirty-
five children (aged 7 months–15.6 years; median, 5.4 years) started ART. Generally, mortality 
among HIV-infected children was highest among those aged <2 years. Intensified efforts to 
prevent mother-to-child transmission of HIV and ensure early HIV diagnosis and treatment are 
required to decrease child mortality caused by HIV in rural Africa [26]. 
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A Retrospective and prospective study was conducted to describe survival outcomes among HIV 
infected children in a multicenter regional cohort in Asia. A statistical method known as 
Multivariate Cox proportional hazard models were used to assess factors associated with 
mortality in children who received ART. In this study 2280 children were enrolled in the study, 
among this 1752 (77%) had received ART. During a median follow up of 3.1 years after ART, 
115 (6.6%) deaths occurred, giving a crude mortality rate of 1.9 per 100 child-years (95% CI, 
1.6-2.4). The mortality rate was highest in the first three months of ART (10.2 per 100 child-
years; 95% CI, 7.5-13.7) and declined after 12 months (0.9 per 100 child-years; 95% CI, 0.7-
1.3). Those with low recent CD4 percentage, who started ART with lower baseline weight-for-
age z-score, or with WHO clinical stage 4 had an increased risk of death. Of 528 (23%) children 
who never received ART, 36 (6.8%) died after presenting to care, giving a crude mortality rate of 
4.1 per 100 child-years (95% CI 3.0-5.7), with a lost-to-program rate of 31.5 per 100 child-years 
(95% CI, 28.0-35.5). Therefore the author concludes that high mortality during the first three 
months of ART and in those with low CD4 percentage support the implementation of early 
diagnosis and ART initiation [27]. 
Another similar study was done to describe the outcomes of antiretroviral therapy (ART) in a 
large cohort of HIV-infected children in Thailand. The data were obtained from four 
collaborative referral sites around the country. At ART initiation, the median age was 7.1 years 
(IQR 3.4–10.0 years), CD4 percentage was 9.0% (IQR 3.0–17.0%), and 61.3% were in World 
Health Organization (WHO) stage 3 or 4. Seventy-four percent were initiated on an NNRTI-
based regimen. The death and lost to follow-up rates were 1.3 (95% confidence interval (CI) 1.1–
1.6) and 2.2 (95% CI 1.6–2.6)/100 patient- years of follow-up, respectively. At the last clinic 
visit of 919 children, the median CD4 percentage was 27.0% (IQR 23.0–32.0%) and 80.2% had 
HIV-RNA <40 copies/ml. WHO stage 1 or 2 at ART initiation was associated with having a viral 
load <40 copies/ml (p < 0.002), and baseline CD4 ≥15% and starting with a three-drug regimen 
were associated with achieving CD4 ≥25% (p < 0.001). Although most children initiated ART at 
low CD4 levels, the majority achieved immune reconstitution and long-term virological control. 
Earlier treatment may improve these outcomes [28]. 
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Another study to identify demographic and clinical risk factors associated with mortality after 
initiation of antiretroviral therapy (ART) in HIV infected children in KwaZulu-Natal, South 
Africa. A retrospective cohort study was done on 537 children initiating antiretroviral therapy at 
McCord Hospital in KwaZulu-Natal, South Africa. Data were extracted from electronic medical 
records and risk factors associated with mortality were assessed using Cox regression analysis. 
There were 47 deaths from the cohort of 537 children initiating ART with over 991 child-years 
of follow-up (median 22 months on ART), yielding a mortality rate of 4.7 deaths per 100 child 
years on ART. Univariate analysis indicated that mortality was significantly associated with 
lower weight-for-age Z-score (p<0.0001), chronic diarrhea (p = 0.0002), lower hemoglobin (p = 
0.002), age<3 years (p = 0.003), and CD4% <10% (p = 0.005). The final multivariable Cox 
proportional hazards mortality model found age less than 3 years    (p = 0.004), CD4 <10% (p = 
0.01), chronic diarrhea (p = 0.03), weight-for-age Z-score (p < 0.0001) and female gender as a 
covariate varying with time (p = 0.03) all significantly associated with mortality. Therefore, in 
addition to recognized risk factors such as young age and advanced immunosuppression, female 
gender was significantly associated with mortality in this pediatric ART cohort [29]. 
A study conducted on 432 children who initiated antiretroviral therapy from June 2006 to June 
2011 at pediatrics ART clinic in Mekelle Hospital, Northern-Ethiopia, to identify independent 
predictors of children’s mortality on ART. The total time contributed by the study participants 
were 14,235 child-months with median follow up of 36 months. The mortality rate of this cohort 
was 1.40 deaths per 1000 child-months or 16.85 deaths per 1000 child-years. Mortality of 
children on ART was low and factors that affect mortality of children on ART were age less than 
18 months, lower CD4 percentage, advanced WHO clinical stage (III&IV), presence of chronic 
diarrhea and lower hemoglobin level all at baseline. The high early mortality rate would support 
the value of an earlier treatment start before development of signs of immunodeficiency 
syndrome despite the method of HIV diagnosis and WHO stage [30]. 
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A multicenter facility-based retrospective cohort study was done in selected pediatric ART units 
in hospitals found in Addis Ababa, Ethiopia. The probability of survival was estimated using the 
Kaplan–Meier method, and multivariate analysis by Cox proportional hazards regression models 
was conducted to determine the independent predictor of survival. A total of 556 children were 
included in this study. Underweight (moderate and severe; HR: 10.10; 95% CI: 2.08, 28.00; P = 
0.004; and HR: 46.69; 95% CI: 9.26, 200.45; P < 0.01, respectively), advanced disease stage 
(WHO clinical stages III and IV; HR: 10.13: 95% CI: 2.25, 45.58; P = 0.003), poor ART 
adherence (HR: 11.72; 95% CI: 1.60, 48.44; P = 0.015), and hemoglobin level less than 7 gm/dl 
(HR: 4.08: 95% CI: 1.33, 12.56; P = 0.014) were confirmed as significant independent predictors 
of death after controlling for other factors. Underweight, advanced disease stage, poor adherence 
to ART, and anemia appear to be independent predictor of survival in HIV-infected children 
receiving HAART at the pediatric units of public hospitals in Ethiopia. Nutritional 
supplementations, early initiation of HAART, close supervision, and monitoring of patients 
during the first 6 months, the follow up period is recommended [31]. 
A study conducted to explore factors affecting survival of children living with HIV/AIDS after 
initiation of ART among HIV-infected children on ART in Ethiopia. Institution based 
retrospective cohort study was employed on 560 children enrolled on ART from January, 2006-
December, 2010.  Multivariable Cox proportional model was fitted to identify factors affecting 
survival after initiation of ART. Children on ART were followed for a median follow up period 
of 47 months (IQR=29, 62). Mortality was high especially during the first sixth months 
following ART initiation. Therefore, close follow up of HIV exposed children to make early 
diagnosis and treatment initiation before the development of severe immune deficiency and 
advanced clinical stage is important [32]. 
Another study on 423 patients identified factors on those patients at a risk of treatment failure 
has shown that the mean survival time (without treatment failure) was 53 months. Females were 
found to have a higher survival time of 57 months and males have significantly higher risk of 
developing treatment failure. Those with two or more episodes of poor adherence during their 
follow-up have a significantly higher failure compared to those with no episode of poor 
adherence. Missed appointment is another independent predictor of treatment failure.  
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The study has shown that non-adherence to medication and clinic visits are associated with 
treatment failure. Following patients closely for their level of adherence and their trend of 
missing clinic visits can be used to help identify those at higher risk of treatment failure. 
Providing intense adherence counseling for these patients may prevent occurrence of failure [33]. 
A retrospective cohort study conducted on identifying the Predictors of mortality among children 
on Antiretroviral Therapy at a referral hospital, Northwest Ethiopia. A total of 549 records were 
included in the analysis. The mean age at initiation of treatment was 6.35 ±3.78 SD years. The 
median follow up period was 22 months. Mortality was 4.0 deaths per 100 child-years of follow-
up period. However, there was a high rate of early mortality. Hence, starting ART very early 
reduces disease progression and early mortality; close follow up of all children of HIV-positive 
mothers is recommended to make the diagnosis and start treatment at an earlier time before they 
develop severe immunodeficiency [34]. 
This study had the objectives to estimate the survival duration and identify socio-economic, 
demographic and clinical predictor variables that affect the survival of HIV-infected children 
under ART.  The data used in this study were obtained from the medical records of 255 HIV-
infected children under the age of 15 who received ART in Felege-Hiwot Referral Hospital, 
Ethiopia. The Kaplan-Meier method and log-rank test allowed for comparison of survival of 
patients in different categories. Identification of predictors of survival was accomplished by 
employing the Cox proportional hazards regression model.  The mean survival time was found to 
be 22.4 months with standard deviation of 0.7 months. Baseline hemoglobin level, WHO clinical 
stage and age had significant impact on the survival of children during the 30 months of follow 
up. The author conclude that the risk of death among HIV-infected children with lower 
hemoglobin level in younger age groups was higher compared to those who were older and had 
higher hemoglobin level; the risk was highest in stage IV which was very similar to that in stage 
III [35]. 
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CHAPTER THREE 
3. Data and Methodology 
3.1. The Data  
The data for this study was obtained from the ART clinic at Gondar University Specialized 
Hospital in Gondar town, Ethiopia. The hospital serves as a teaching and referral center for the 
population of Gondar zone and other adjacent zones and regions in northern Ethiopia. The 
hospital serves as a referral hospital for nearby lower level hospitals and health centers. 
The hospital has a separate unit for the ART program. Gondar University Hospital launched 
ART treatment service in July 2003 for People Living With HIV/AIDS (PLWHA) who are 
financially strong and have the capability to pay for ART according to the national treatment 
guidelines. Later by the year 2005 the hospital started to register and give free ART services for 
those who fulfill standard diagnostic criteria to start ART. Gondar University teaching hospital 
provides care to HIV-infected adults and children through the government free antiretroviral 
treatment program since 2005, with additional support from the nongovernmental organization 
such as I-TECH Ethiopia. Gondar University teaching hospital ART unit is well staffed with 
ART trained physicians, nurses, counselors and laboratory technicians working full time. The 
hospital is under the Amhara Administration Health Bureau and gets technical and financial 
support from I-TECH. 
The data for the study were obtained from patients’ follow up records of a total of 756 children 
on ART follow ups during the study period from the HIV cohort database. However, only 269 
patients with a full record of variables who started ART between 2008 and 2013 were included 
and followed until April 2015 in Gondar University Hospital. The data were collected based on 
the child’s identification number in HIV cohort database without any direct contact with a child 
so as to maintain the confidentiality of the child’s record. Demographic data, laboratory and 
clinical information of all children aged <15 years who started ART were included.  
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3.2. Variables in the Study 
3.2.1. The Response Variable 
The response variable in the study is the survival time of HIV-infected children measured in 
months after starting ART. This is measured as the time a child was followed up from the time 
the child began to receive treatment, until the time to an event (death) or they were lost to follow 
up (for those right censored subjects). 
3.2.2. Explanatory Variables/factors 
The independent variables (predictor variables) included in the study are factors that influence 
the survival status of children. The study focused only on demographic variables (Age, Gender) 
and clinical/immunological variables (Baseline Weight, WHO Clinical Stage, Prophylaxis taken, 
Baseline functional status, Baseline TB status, Reason for taking ART, baseline CD4 count, Total 
lymphocytes counts, baseline hemoglobin levels, Opportunistic Illness, Type of ART drug) that can 
affect the survival time of HIV-infected children.  
Table 3.1: Explanatory variables/factors included in the study 
Explanatory variables / factors Value labeled 
Age  Ages less than 1.5 years = 0 
Ages between 1.5-5 years = 1 
Ages between 5 - 14 years = 2 
Gender Male = 0 
Female=1 
WHO Clinical Stage Clinical Stage- I = 1 
Clinical Stage- II = 2 
Clinical Stage- III = 3 
Clinical Stage- IV = 4 
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CD4 count 
Cut off point for CD4 lymphocyte counts for different age groups 
were those that related to the category of severe immunodeficiency: 
For those younger than one year : less than 1500 cell/μl 
For those between 1-3 years age :less than 750 cell/μl 
For those between 3-5 years age :less than 350 cell/μl 
For those older than 5 years age: less than 200 cell/μl are considered 
as below the threshold. 
 
 
Above the threshold = 0 
Below the threshold =1 
Prophylaxis taken No = 0 
Yes = 1 
Baseline functional status 
Working: means actively participates in age appropriate activities. 
Ambulatory: means limited tolerance for activities 
Bedridden: means no tolerance for activities. 
Working = 0 
Ambulatory = 1 
Bedridden = 2 
Baseline Weight (in kg)  
Total lymphocytes count (cell/μl)  
Hemoglobin level Less or equal to 7.00 gm/dl = 0 
7.00-8.50 gm/ dl =1 
8.50- 10.00 gm/dl =2 
More than 10.00 gm/dl = 3 
Baseline TB status Positive=0 
Negative=1 
Reason for taking ART Clinical=1 
CD4=2 
CD4 + Clinical=3 
CD4 + Lymphocytes =4 
Opportunistic Illness Yes=1 
No=0 
 
 
Type of ART drug 
D4t-3TC-NVP = 0 
D4t-3TC-EFV = 1 
AZT-3TC-NVP = 2 
AZT-3TC-EFV = 3 
Other drugs =4 
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3.3. Methodology 
3.3.1. Basic Concepts on Survival Analysis 
Survival analysis is the phrase used to describe the analysis of data that correspond to the time 
from a well-defined time origin until the occurrence of some particular event or end-point. 
Survival data are not amenable to standard statistical procedures used in data analysis. One of the 
features of survival data that renders standard methods inappropriate is that survival times are 
frequently censored. The survival time of an individual is said to be censored when the end-point 
of interest has not been observed for that individual. 
Survival data can be include survival time, response to a given treatment, and patient 
characteristics related to response, survival, and the development of a disease.  
There are three primary goals of survival analysis: to estimate and interpret survival and / or 
hazard functions from the survival data; to compare survival and / or hazard functions, and to 
assess the relationship of explanatory variables to survival time. Survival analysis provides a 
great tool for analyzing the time to an event type of data. 
3.3.2. Descriptive Methods for Survival Data 
In survival analysis, it is always a good idea to present numerical or graphical summaries of the 
survival times for the individuals. Before beginning any statistical investigation, we should 
perform a thoughtful and thorough univariate and bivariate analysis of the data so as to obtain a 
clear sense of the distributional characteristics of the outcome variable and to identify 
explanatory variables/factors that explain the survival time of children. The estimation of the 
survival distribution provides estimates of descriptive statistics such as the median survival time 
which is appropriate in a study of survival time. 
The fact that some of our observations of the outcome variable, survival time are incomplete is a 
problem for conventional univariate summary statistics such as the mean, median and standard 
deviation, etc. In this situation, we must obtain an estimate of the cumulative distribution 
function in order to obtain values of statistics which summarize the survival data. Summary 
values are at the heart of statistical analysis. Survivor and hazard functions are the two functions 
of central interest in summarizing survival data [40]. 
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In practice, the actual date recorded will be the date on which each individual enters the study, 
and the date on which each individual dies or was last known to be alive. The survival time in 
days, weeks or months, whichever is the most appropriate, can then be calculated. Survivor 
function and hazard function are the two functions of central interest in summarizing survival 
data. The actual survival time of an individual, 𝑡, can be regarded as the value of a random 
variable T, which can take any non-negative value. The different values that 𝑇 can take have a 
probability distribution, and we call 𝑇 the random variable associated with the survival time. 
When the random variable T has a probability distribution with underlying probability density 
function 𝑓(𝑡), the distribution function of 𝑇 is then given by 
𝐹 (𝑡) =  𝑃 (𝑇 < 𝑡) … . (3.1) 
and 𝐹 (𝑡) represents the probability that the survival time is less than some value 𝑡. The survivor 
function, 𝑆(𝑡), is defined to be the probability of children whose survival time greater than or 
equal to t, and so 
𝑆(𝑡) =  𝑃 (𝑇 ≥  𝑡) =  1 –  𝐹(𝑡)…… (3.2) 
The probability density function (pdf) of 𝑇, 𝑓(𝑡) gives the probability of deaths occurring at  
time 𝑡. 
This is the chance that a child chosen at random will die at time t.  
 
𝑓(𝑡) =
𝑑𝐹(𝑡)
𝑑𝑡⁄ = 0
lim
t
𝐹(𝑡+∆𝑡)
∆𝑡
=
0
lim
t
𝑃(𝑡≤𝑇≤𝑡+∆𝑡)
∆𝑡
=
𝑑(1−𝑠(𝑡))
𝑑𝑡
=
−𝑑𝑠(𝑡)
𝑑𝑡
……(3.3) 
The survivor function can therefore be used to represent the probability that a child dies at time 𝑡, 
conditional on having survived to that time.  
That is, the function represents the instantaneous death rate for a child surviving to time 𝑡, thus, 
the hazard function, ℎ(𝑡), is defined as 
  ℎ(𝑡) = lim∆𝑡→0
𝑃(𝑡≤𝑇<𝑡+∆𝑡 𝑇⁄ ≥𝑡)
∆𝑡
 
           = lim∆𝑡→0
𝑃(𝑡≤𝑇≤𝑡+∆𝑡,𝑇≥𝑡)
𝑃(𝑇≥𝑡)⁄
∆𝑡
             
           = lim
∆𝑡→0
𝑃(𝑡≤𝑇≤𝑡+∆𝑡,𝑇≥𝑡)
∆𝑡
×
1
𝑃(𝑇≥𝑡)
= 𝑓(𝑡) ×
1
𝑠(𝑡)
=
𝑓(𝑡)
𝑠(𝑡)
…………… ..(3.4)  
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From this definition the relationship between the survivor and hazard function, can be expressed 
as 
ℎ(𝑡) =
𝑓(𝑡)
𝑆(𝑡)
= 
−𝑑
𝑑𝑡
{ln 𝑆(𝑡)}……………………(3.5) 
Where 𝑓(𝑡) is the probability density function of  𝑇. 
The estimation of survival experience of different groups of explanatory variables can be done 
using a non-parametric or distribution-free method known as the Kaplan-Meier estimator of the 
survivorship function [39]. 
3.3.2.1. The Kaplan-Meier Estimator of the Survivorship Function 
The Kaplan-Meier estimator of the survival function also called the product limit estimator. This 
method is non-parametric or distribution-free, since it does not require specific assumption to be 
made about the underlying distribution of the survival times [41]. 
To apply the Kaplan-Meier method suppose that there are 𝑛 independent individuals in a random 
sample with observed survival times 𝑡1, 𝑡2, … , 𝑡𝑛. The distinct ordered failure times observed 
among the n individuals are 𝑡(1), 𝑡(2), … , 𝑡(𝑟), 𝑟 < 𝑛 as there are more than one individual with the 
same observed survival time and some of the observations may be right-censored, i.e., the 
survival status of the individual might not be known at the time of the analysis. 
The probability of survival at time 𝑡(j), 𝑃 (𝑡(j)) is then estimated by 
𝑃 (𝑡(𝑗)) =
 𝑛𝑗 − 𝑑𝑗
𝑛𝑗
… . . (3.6) 
Where 𝑛j is the number of individuals who are alive just before time t(j) and dj is the number who 
die at this time. 
The KM estimator is a nonparametric estimator of the survivor function S(t). 
?̂?(𝑡) = ∏(1 −
𝑑𝑗
𝑛𝑗
)
𝑡𝑗≤𝑡
…… . (3.7) 
With the convention that  ?̂?(𝑡) = 1 𝑖𝑓 𝑡 ≤ 𝑡1. Where 𝑑𝑗 is the number of individuals who 
experience the event or failure at time 𝑡𝑗 , and 𝑛𝑗  is the number of individuals who have not yet 
experienced the event at that time and are therefore still at risk for experiencing it.  
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The Kaplan-Meier estimator is a step function with jumps at the observed event times. The size 
of the jump at a certain event time 𝑡(𝑗)  =  𝑡(𝑖) depends on the number of events observed at 𝑡i, as 
well as on the pattern of the censored event times before. 
The standard error of the KM survival estimator which is also known as the Greenwood’s 
formula (39) is  
𝑆𝑒{?̂?(𝑡)} = ?̂?(𝑡) {∑
𝑛𝑗
𝑛𝑗(𝑛𝑗 − 𝑑𝑗)
𝑘
𝑗=1
}
1/2
, 𝑓𝑜𝑟 𝑡(𝑘) ≤ 𝑡 < 𝑡(𝑘+1) ……………(3.8) 
 
The Kaplan-Meier estimator of the survivorship functions has to be obtained separately for each 
group of study subjects. 
Survivorship function can also be estimated using the relationship 
?̂?(𝑡) = 𝑒−?̂?(𝑡) …… . . (3.9) 
Where   ?̂?(𝑡) = ∫ ℎ(𝑢)𝑑𝑢
𝑡
0
. 
The function ?̂?(𝑡) is called the cumulative hazard function and it plays a central role in 
regression modeling of survival time data.  
To see how survival function related with the cumulative hazard function as given above, let us 
begin at the hazard function in equation (3.5) h(t) as: 
                            ℎ(𝑡)  =  𝑓(𝑡) / 𝑆(𝑡)  =  
−𝑑 ln𝑆(𝑡)
𝑑𝑡
=−ℎ(𝑡) =
𝑑 ln𝑆(𝑡)
𝑑𝑡
 
ln 𝑆(𝑡) = −∫ℎ(𝑢)𝑑𝑢
𝑡
0
 
𝑆(𝑡) = 𝑒−∫ ℎ(𝑢)𝑑𝑢
𝑡
0 = 𝑒−𝐻(𝑡) 
This expression suggests that if we can specify the hazard function, ℎ(𝑡), then it is relatively easy 
to obtain an expression for any of the other functions of survival time T. Hence, we need to 
specify a regression model type of the hazard function as a function of time and covariates. 
22 
 
3.3.3. Regression Models for Survival Data 
In modeling survival data we explore how the survival experience of a group of individuals 
depends on the values of one or more explanatory variables, whose values have been recorded 
for each individual at the time origin. The hazard function is modeled directly in survival 
analysis. There are two broad reasons to model survival data. One objective of the modeling 
process is to determine which combinations of potential explanatory variables affect the form of 
the hazard function. Another reason for modeling the hazard function is to obtain an estimate of 
the hazard function itself. This may be of interest in its own right, but in addition, from the 
relationship between the survivor function and hazard function an estimate of the survivor 
function can be found [42]. 
A variety of models and methods have been developed for doing this sort of survival analysis 
using either parametric or semi-parametric approaches. One of the most popular types of 
regression models used in survival analysis is the Cox proportional hazard model [38]. 
3.3.3.1. Cox-Proportional Hazards Regression Model 
Cox-proportional hazard model is not a pure parametric method since it does not assume any 
functional form of distribution of hazard rate. However, it assumes that hazard function of any 
two individuals is proportional with the ratio being determined by the covariates that is constant 
over time. Clearly, if one is unsure of the functional form of hazard function, adopting a semi-
parametric approach would be the preferred alternative to imposing specific parametric 
assumptions.  
The Cox regression model is used to determine which combinations of explanatory variables 
affect the form of the hazard function. Also the model is used to obtain an estimate of the hazard 
function itself for an individual who may be of interest in its own right. But in addition, from the 
relationship between the survivor function and hazard function, an estimate of the survivor 
function can be found. 
Cox regression model is somewhat different in form from linear models encountered in 
regression analysis and in the analysis of data from designed experiments, where the dependence 
of the mean response, or some function of it, on certain explanatory variables is modeled. 
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However, many of the principles and procedures used in linear modeling carry over to the 
modeling of survival data. The Cox regression model can be used for data that contain censored 
observations. The model also takes into account the fact that the probability of experiencing an 
event differs with duration of exposure to risk. 
The semi-parametric Cox proportional hazards model is the most commonly used model in 
hazard regression.  Let t denote a continuous non-negative random variable representing survival 
time. The basic Cox model is as follows: 
ℎ(𝑡|𝑿) = ℎ0(𝑡) exp(𝜷
′𝑿) , ………………………… . . …………(3.10) 
Where: 
 ℎ(𝑡|𝑿) hazard function at time t with covariates 𝑿 = (𝑋1, 𝑋2, . . . 𝑋𝑝)’ 
 ℎ0(𝑡) is the arbitrary baseline hazard function that characterizes how the hazard function 
changes as a function of survival time. No particular shape is assumed for the baseline 
hazard; it is estimated non-parametrically. 
 𝜷′ = (𝛽1, 𝛽2, … , 𝛽𝑝)  is a column vector of p regression parameters associated with 
explanatory variables. 
 exp(𝛽′𝑥) Characterizes how the hazard function changes as a function of subject 
covariates. The contributions of covariates to the hazard are multiplicative. 
 
The baseline hazard is treated non-parametrically, but the individual covariate effects 
𝑥1, 𝑥2, … , 𝑥𝑝 are assumed to be constant throughout the study, hence the notation is semi-
parametric. The model is often called the proportional hazards model because of this constant 
covariate effect throughout the study. If two individuals are compared that have covariate values 
𝑿 and 𝑿*, the ratio of their hazard rates at any time point simplifies to: 
ℎ(𝑡|𝑿)
ℎ(𝑡|𝑿∗)
=
ℎ0(𝑡) exp(𝜷
′𝑿)
ℎ0(𝑡) exp(𝜷′𝑿∗)
= exp{𝜷′(𝑿 − 𝑿∗)}……………… . . (3.11) 
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This hazard ratio is constant or proportional throughout the study, so that equation (3.11) does 
not depend on t. This assumption greatly facilitates the interpretation of covariate effects, as the 
effect of a given covariate compared to the absence of that covariate is expressed as a single 
constant.  
This does not however imply that the absolute difference between the two individuals discussed 
above is constant; the exponentiated covariates act multiplicatively on a baseline hazard which 
may vary freely over time. 
The Cox proportional hazards model can equally be regarded as linear model, as a linear 
combination of the covariates for the logarithm transformation of the hazard ratio given by: 
log [
ℎ(𝑡|𝑿)
ℎ0(𝑡)
] = 𝜷′𝑿………………….. (3.12) 
 
Where 𝑿 = (𝑋1, 𝑋2, . . . 𝑋𝑝)’ is the value of the vector of explanatory variables for a particular 
individual and 𝜷′ = (𝛽1, 𝛽2, … , 𝛽𝑝)   is a vector of coefficients. 
Again the cumulative hazard function is given by: 
𝐻(𝑡) = 𝐻0(𝑡) exp(𝜷
′𝑿)…………………. (3.13) 
 
Another way to specify the distribution of survival time is through the hazard function. Thus, the 
survival function given by the Cox proportional hazard function is 
𝑆(𝑡|𝑿) = [𝑆0(𝑡)]
exp(𝜷′𝑿), …………………(3.14) 
   Where 𝑆0(𝑡) = 𝑒
−𝐻0(𝑡) is the baseline survivorship function. 
3.3.3.2. Assumption of Cox-proportional Hazards Regression Model 
The proportional hazards assumption is vital to the interpretation and use of a fitted proportional 
hazards model. Specifically considering the semi-parametric assumption, the ratio of hazard 
functions for any two individuals is constant over time and is determined by the individuals’ 
covariate values.  
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Cox proportional hazards regression assumes that different groups have similar shaped hazard 
functions or assumes that any two groups have constant relative risk over time. That is, 
 Study group j has a hazard function ℎ𝑗(𝑡|𝑥) that is a positive multiple of the baseline hazard 
as:   ℎ𝑗 (𝑡|𝑥) = ℎ0(𝑡) exp(𝛽
′𝑥). 
 There is a baseline hazard function ℎ0(𝑡) common to all individuals in all the study groups. 
 Explanatory variables act only on the hazard ratios,exp(𝛽′𝑥), and they do not affect the 
baseline hazard (i.e. proportional hazard assumption). 
3.3.4. Comparison of Survival Functions 
After providing a description of the overall survival experience in the study, we turn our 
attention to a comparison of the survivorship experience in key subjects in the data. The simplest 
way of comparing the survival times obtained from two or more groups is to plot the Kaplan-
Meier curves for these groups on the same graph. However, this graph does not allow us to say, 
with any confidence, whether or not there is a real difference between the groups. The observed 
difference may be a true difference, but equally, it could also be due merely to chance variation. 
Assessing whether or not there is a real difference between groups can only be done, with any 
degree of confidence, by utilizing statistical tests. 
When comparing groups of subjects, it is always a good idea to begin with a graphical display of 
the data in each group. The figure in general shows if the pattern of one survivorship function 
lies above another, meaning that he group defined by the upper curve lived longer, or had a more 
favorable survival experience, than the group defined by the lower curve. 
The statistical question is whether the observed difference in the graph is significant or not. A 
test procedure must be developed for judging whether there is a statistically significant 
difference in survival experience between groups or not. A number of statistical tests have been 
proposed to answer this question among the various non-parametric tests one can find in the 
statistical literature (43), the Mantel-Haenzel test, currently called the “log-rank” is the one 
commonly used non-parametric test for comparison of two or more survival distributions. 
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3.3.4.1. Log-Rank Test 
The log rank test, developed by Mantel and Haenszel, sometimes called the Mantel-Haenszel test 
is a non-parametric test for comparing two or more independent survival curves. Since it is a 
non-parametric test, no assumptions about the distributional form of the data need to be made. 
This test is however most powerful when used for non-overlapping survival curves. This test can 
be generalized to accommodate other tests that are equally used sometime in practice such as 
Generalized Wilcoxon test, Tarone-Ware test, and Peto-Peto Prentice test. Each of these tests 
uses different weight to adjust for censoring that is often encountered in survival data. 
The test statistic used is obtained by computing the difference between the observed and 
expected number of deaths in each group of the study subjects.  
The calculation of each test is based on a contingency table of groups by status at each observed 
survival time. 
The log rank test statistic for comparing two groups is given by: 
𝑄 =
[∑ (𝑑1𝑖−?̂?1𝑖)
𝑚
𝑖=1 ]
2
∑ ?̂?1𝑖
𝑚
𝑖=1
………………………………………  (3.15) 
Where: 𝑚 is the number of rank ordered event times. 
𝑑1𝑖   is the observed number of events (the number of patients resumed to      
                  treatment) in group1 at event time 𝑡𝑖. 
?̂?1𝑖 =
𝑛1𝑖𝑑𝑖
𝑛𝑖
  is the expected no of events corresponding to 𝑑1𝑖  . 
𝑛1𝑖   is the number of individuals at risk in group1 just prior to event time 𝑡𝑖. 
?̂?1𝑖 =
𝑛1𝑖𝑛0𝑖𝑑𝑖(𝑛𝑖−𝑑𝑖)
𝑛𝑖
2(𝑛𝑖−1)
  is the variance of the number of events 𝑑1𝑖  at time 𝑡𝑖  
𝑛𝑖  is the number of individuals at risk in both groups1 and 2 just prior to event time 𝑡𝑖. 
Under the null hypothesis that the two survivorship functions are the same, and assuming that the 
censoring experience is independent of group, and that the total number of observed events and 
the sum of the expected number of events is large, then the significance of Q may be tested using 
the chi-square distribution with one degree of freedom.  
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The most frequently used test, the log rank test, sometimes called the Mantel-Haenszel test, is the 
most well-known and widely used test, this test is based on weights equal to one. 
Then the hypothesis to be tested becomes 
 
                        𝑯𝟎 ∶ 𝑆1(𝑡) = 𝑆2(𝑡) = 𝑆3(𝑡) = ⋯ = 𝑆𝐾(𝑡)     Against 
                        𝑯𝟏 ∶ 𝑁𝑜𝑡 𝐻0  
The test rule used is: 
There is no statistically significant difference in survival experience between groups at 𝛼 level of 
significance if the computed value of 𝑸𝑳𝑹 < 𝒙(𝒌−𝟏)
𝟐
 i.e. do not reject 𝐻0. 
There is statistically significant difference in survival experience between groups at 𝛼 level of 
significance if the computed value of 𝑸𝑳𝑹 ≥ 𝒙(𝒌−𝟏)
𝟐
 i.e. reject 𝐻0. 
The log rank test can be extended for comparing three or more groups of survival experience. 
See details in (40). 
3.3.4.2. Fitting the Cox-proportional Hazards Regression Model 
The data in survival analysis based on the sample size n are denoted by the triplet (𝑡𝑖, 𝛿𝑖 , 𝑥𝑖),  
 𝑖 = 1, 2, … , 𝑛. Where 𝑡𝑖 is the time at which the 𝑖
𝑡ℎ
 individual experience the event from the 
disease of interest, 𝛿𝑖 is the event indicator 𝛿𝑖 = 1 if the event has occurred and 𝛿𝑖 = 0 if it is 
censored (the lifetime may be right or interval censored), and 𝑥𝑖 is the vector of covariates or the 
risk factors for the 𝑖𝑡ℎ individual. 
The Cox model will be fitted by estimating the unknown regression coefficients through the 
maximum likelihood method. The actual likelihood function is constructed by considering the 
contribution of the probability that a subject with covariate value x dies from the disease of 
interest at time 𝑡 (i.e. , 𝑓 (𝑡, 𝛽, 𝐱)), and the probability that a subject with covariate value x 
survives at least 𝑡 time units(i.e. , 𝑆 (𝑡, 𝛽, 𝐱)). That is, under the assumption of independent 
observations, the full likelihood function is obtained by multiplying the respective contributions 
of the observed triplets, a value of 𝑓 (𝑡, 𝛽, 𝒙) for a non-censored observation and a value of 
𝑆 (𝑡, 𝛽, 𝐱) for censored observations. 
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Thus, the contribution of each triplet to the likelihood is the expression 
[𝑓 (𝑡, 𝛽, 𝐱)]𝛿𝑖 × [𝑆 (𝑡, 𝛽, 𝐱)]1−𝛿𝑖 ………………………………………… . . (3.16) 
Since the observations are assumed to be independent, the likelihood function is the product of 
the expression in (16) over the entire sample and is formulated as: 
𝑙(𝛽) = ∏{[𝑓 (𝑡𝑖, 𝑥𝑖 , 𝛽)]
𝛿𝑖 × [𝑆 (𝑡𝑖, 𝑥𝑖 , 𝛽)]
1−𝛿𝑖}
𝑛
𝑖=1
……… . (3.17) 
Then, the full maximum likelihood function can be further simplified as 
𝑙(𝛽) = ∏{[ℎ(𝑡𝑖, 𝑥𝑖, 𝛽) × 𝑆 (𝑡𝑖, 𝑥𝑖 , 𝛽)]
𝛿𝑖 × [𝑆 (𝑡𝑖, 𝑥𝑖, 𝛽)]
1−𝛿𝑖}
𝑛
𝑖=1
 
                                      = ∏{[ℎ(𝑡𝑖, 𝑥𝑖 , 𝛽)]
𝛿𝑖 × [𝑆 (𝑡𝑖, 𝑥𝑖 , 𝛽)]}
𝑛
𝑖=1
………………………………(3.18) 
 
Where 
 ℎ(𝑡𝑖 , 𝑥𝑖 , 𝛽) = ℎ0(𝑡𝑖)𝑒
𝑿𝒊
′𝜷  is the hazard function for individual i. 
 𝑆 (𝑡𝑖 , 𝑥𝑖 , 𝛽) = 𝑆0(𝑡𝑖)
exp (𝑿𝒊
′𝜷)  is the survival function for individual i. 
When we rewrite the maximum likelihood it becomes 
𝑙(𝛽) = ∏{[ℎ0(𝑡𝑖)𝑒
𝑿𝒊
′𝜷]
𝛿𝑖
× [𝑆0(𝑡𝑖)
exp (𝑿𝒊
′𝜷)]}
𝑛
𝑖=1
……………(3.19) 
Cox (1972) proposed using an expression he called a partial likelihood function due to the fact 
that the likelihood formula considers probabilities only for those subjects who fail, and does not 
explicitly consider probabilities for those subjects who are censored. In other words, the 
likelihood for the Cox model does not consider probabilities for all subjects. Let us consider a 
sample of n subjects and suppose a total of m failures occur, with m smaller than n, due to the 
presence of censoring. Let 𝑡1, 𝑡2, … , 𝑡𝑚  be the m distinct ordered failure times observed and let 
𝑅(𝑡𝑖) be the set of individuals at 𝑖 
𝑡ℎ failure time, which consists of all subjects with survival or 
censored times greater than or equal to the specified time [41].  
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Thus the partial likelihood is given by the expression: 
𝑙𝑝(𝛽) = ∏[
𝑒𝑿𝒊
′𝜷
∑ 𝑒𝑿𝒋
′𝜷
𝑗𝜖𝑅(𝑡𝑖)
]
𝛿𝑖
…………… . (3.20)
𝑛
𝑖=1
 
The expression assumes that there are no tied times, and designed in such a way that it excluded 
terms when 𝛿𝑖 = 0. As a result the equation in (20) becomes, 
𝑙𝑝(𝛽) = ∏
𝑒𝑿𝒊
′𝜷
∑ 𝑒𝑿𝒋
′𝜷
𝑗𝜖𝑅(𝑡𝑖)
𝑚
𝑖=1
  ………………(3.21) 
To obtain the maximized likelihood with respect to the parameters of interest, β, we maximize 
the log partial likelihood function as 
𝐿𝑝(𝜷) = ∑{𝑿𝒋
′𝜷 − ln ( ∑ 𝑒𝑿𝒋
′𝜷
𝑗𝜖𝑅(𝑡𝑖)
)}
𝑚
𝑖=1
………… . (2.22) 
Observe that the log-partial likelihood is only a function of 𝜷’s. 
We obtain the maximum partial likelihood estimator by differentiating the right hand side of 
(2.22) with respect to 𝛽, setting the derivatives equal to zero and solving for the unknown 
parameters. This is known as the Newton-Raphson iterative method.  
That is, for each derivative 
𝐿𝑝(𝜷) = ∑{𝑿𝒋
′𝜷 − ln ( ∑ 𝑒𝑿𝒋
′𝜷
𝑗𝜖𝑅(𝑡𝑖)
)}
𝑚
𝑖=1
. 
Differentiate the log-partial likelihood with respect to 𝜷𝒌’s, 𝑘 =  1, … , 𝑝 
𝜕𝐿𝑝(𝜷)
𝜕𝛽𝑘
=
𝜕 ∑ {𝑿𝒋
′𝜷 − ln [∑ 𝑒𝑿𝒋
′𝜷
𝑗𝜖𝑅(𝑡𝑖) ]}  
𝑚
𝑖=1
𝜕𝛽𝑘
 
                                                            = ∑{𝑋𝑖𝑘 −
∑ 𝑋𝑗𝑘𝑒
𝑿𝒋
′𝜷
𝑗𝜖𝑅(𝑡𝑖)
∑ 𝑒𝑿𝒋
′𝜷
𝑗𝜖𝑅(𝑡𝑖)
}
𝑚
𝑖=1
………………………… . (3.23) 
 
Where 𝑋𝑖𝑘  is the value of the covariate 𝑋𝑘for the subject with observed ordered survival time 𝑡(𝑖). 
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The above partial derivatives with respect to each 𝜷 which is coefficient of each covariates 
equated to zero and yield 𝑝 equations. 
[
 
 
 
 
 
 
 
 
𝜕𝑙(𝛽)
𝛽1
𝜕𝑙(𝛽)
𝛽2.
.
.
𝜕𝑙(𝛽)
𝛽𝑝 ]
 
 
 
 
 
 
 
 
=
[
 
 
 
 
 
 
 
 
0
0
.
.
.
.
.
.
0]
 
 
 
 
 
 
 
 
…………………………(3.24) 
 
We obtain the partial likelihood estimates of 𝜷 by using Newton-Raphson algorithm or any other 
numerical optimization techniques. 
To test the significance of each parameter estimate we need to have a measure of variation by 
defining observed 𝑝 × 𝑝 information matrix as: 
𝑙0(𝜷) =
−𝜕2𝑙𝑝(𝜷)
𝜕𝜷𝜕𝜷′
………… . . (3.25) 
The estimated variance-covariance matrix is the inverse of the above observed information 
matrix 
?̂? = [𝑙0(?̂?)]
−1
………… . (3.26) 
The estimator ?̂?~𝑁(𝜷, 𝛴), and ?̂? is asymptotically unbiased. 
However, this estimation procedure is valid only for data in which no more than one event occur 
at the same time even if it is quite common for survival data to contain tied event times. The 
maximum partial likelihood estimates for 𝜷 in the presence of ties is obtained in the same 
manner as in non-tied data cases what we have seen except that the derivatives are taken with 
respect to the unknown parameters in the logarithm of either the Breslow or the Efron-
approximation to the partial likelihood given below. 
The Breslow approximation to the partial likelihood in case of tied data is handled by  
𝑙𝑝𝐵(𝛽) = ∏
𝑒𝑥(𝑖)+𝛽
[∑ 𝑒𝑥𝑗𝛽𝑗∈𝑅(𝑡(𝑖)) ]
𝑑𝑖
……………(3.27)
𝑚
𝑖=1
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Where, 𝑑𝑖 denotes the number of subjects with survival time 𝑡(𝑖) and (𝑖)
+ is the sum of covariate 
over the 𝑑𝑖 subjects. 
The Efron-approximation to the partial likelihood is more complicated and yields slightly better 
approximation to the exact partial likelihood than the Breslow approximation. It uses as the 
partial likelihood 
𝑙𝑝𝐵(𝛽) = ∏
𝑒
𝑥(𝑖)+𝛽
∏ [∑ 𝑒
𝑥𝑗𝛽
𝑗∈𝑅(𝑡(𝑖))
−
𝑘−1
𝑑𝑖
∑ 𝑒
𝑥𝑗𝛽
𝑗∈𝐷(𝑡(𝑖))
]
𝑑𝑖
𝑘=1
𝑚
𝑖=1   [40]…… ……….… (3.28) 
3.3.5. Model Selection 
Model development in proportional hazards regression analysis requires critical decisions in 
selecting subsets of covariates as it is likely that more covariates are present in real life problems; 
selection of interaction terms to be included in the model and checking the linearity of 
continuous covariates and choosing the appropriate transformation for non-linear covariates. The 
methods of selecting a subset of covariates in a proportional hazards regression model are   
essentially similar to those used in any other regression models. The most common methods are 
purposeful selection, step-wise (forward selection and backward elimination) and best sub-set 
selections. Survival analysis using Cox regression method begins with a thorough univariable 
analysis of the association between survival time and all important covariates [41]. 
Usually, we may suspect more covariates/factors that influence the response variable than we can 
reasonably select to include in the model. So we must decide on a method to select a subset of 
total number of covariates to be included in the model. When selecting a subset of covariates we 
must consider clinical importance and statistical significance of the set of covariates. 
We made a thorough bivariate analysis of the association between survival time and all important 
covariates in the set. This includes Kaplan-Meier estimates of group specific survivorship 
functions, point and interval estimates of the median survival time and Log-rank test of 
significance to compare survival experience across the groups defined by the categorical 
variables. We grouped some of the continuous covariates into clinically meaningful groups and 
the above methods of categorical covariates will be applied. 
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All designed and influential variables significant in the bivariate analysis at p-value less than 
0.25 will be included in the multivariable model. Using 0.25 as level of significance resulted in 
the inclusion of covariates that have the potential to be either an important confounder or 
statistically significant in the preliminary multivariable model. 
We fit multivariable Cox proportional hazards regression model using the statistical packages 
SPSS and STATA. For the initial multivariable model, we use the p-values from the Wald test of 
individual coefficients to identify covariates that might be deleted from the model. At this step, 
since some covariates may not look significant, we should take care not to delete important 
covariates. This is especially important when a nominal scale covariate with more than one 
design variable has been selected for deletion. For instance, the categorical predictor clinical 
stage has four levels and therefore we will include this predictor using three dummy variables 
with the group clinical stage IV as the reference group. We do the same for categorical variables 
such as functional status, reason for ART and types of ART. 
When a covariate is selected for deletion, we should assess whether or not removal of the 
covariate has produced a significant change in the coefficient of the variables retained in the 
model. If the change in one of the coefficients of the remaining covariates as a result of deletion 
of a covariate from the preliminary model, is about 25% or more then we considered this a 
significant change and the variable that was removed should be added back in to the model as it 
might be an important confounder. 
3.3.6. Assessment of Model Adequacy for Cox Proportional Hazard Model 
Model-based inferences depend completely on the fitted statistical model. For these inferences to 
be valid in any sense of the word, the fitted model must provide an adequate summary of the data 
upon which it is based. The methods for assessment of a fitted proportional hazards model are 
essentially the same as for other regression models [41]. 
Residuals are used to investigate the lack of fit of a model and useful for examining different 
aspects of the model. The following residuals have been proposed for use by different authors in 
connection with the Cox regression model. 
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3.3.6.1. Residual Analysis 
A residual is the difference between the observed value of the outcome variable and that value 
predicted by the model. The two key assumptions in the definition of a residual are the value of 
the outcome is known and the fitted model provides an estimate of the mean of the dependent 
variable or systematic component of the model. However, the two assumptions are not valid 
when using partial likelihood to fit the proportional hazards model to censored survival data. The 
absence of an obvious residual had influence the development of several different residuals, each 
of which plays an important role in examining some aspect of the fit of the proportional hazard 
model. These include the Cox-Snell, martingale and Schoenfeld residuals [39 & 41]. 
Cox-Snell Residuals (𝒓𝒄𝒊) are residuals most widely used in the analysis of survival data. The 
Cox-Snell residual for the 𝑖 𝑡ℎsubject is given by 
𝒓𝒄𝒊 = ?̂?𝑖(𝑡) = −?̂?𝑖(𝑡)………………… . (3.29) 
 Where ?̂?𝑖(𝑡) and ?̂?𝑖(𝑡)are the estimated values of the cumulative hazard and survivor 
functions of the 𝑖𝑡ℎ subject at time 𝑡, respectively.  
In nut shell, Cox-Snell residuals are useful in assessing an overall model fit. If the plot of Cox-
Snell residuals are close to the 450 straight line through the origin. This indicates that the model 
fit to the data very well.  
Martingale Residuals (𝒓?̂?𝒊) are also called modified Cox-Snell residuals and, expressed as 
𝒓?̂?𝒊 = 𝛿𝑖−?̂?𝑖(𝑡) = 𝛿𝑖 − 𝑟𝑐𝑖 …………(3.30) 
Where 𝛿𝑖 = 1 for uncensored observations and zero otherwise, and 𝑟𝑐𝑖 are Cox-Snell residuals. 
These residuals have similar properties to the error components in other models, in addition to 
the properties that its mean is equal to zero under the correct model. In large samples, the 
martingale residuals are uncorrelated with one another and have an expected value of zero. 
However, the martingale residuals are not symmetrically distributed about zero. 
Plot of Martingale versus explanatory variables is used to indicate whether any particular 
variable needs to be transformed before incorporating it in the model. In other way round, 
martingale residuals are useful in determining the linearity of continuous covariates to be 
included in the model.  
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If after plotting the residuals versus explanatory variables, the plot does not show an obvious 
relationship, then the variable is not important in the model to be included. Therefore, if most of 
the points fall horizontally about zero, in the plots of the martingale residuals versus the values 
of the independent variables, then the fitted model is taken as satisfactory. 
Schoenfeld Residuals (𝒓𝒔𝒊𝒌) 
Schoenfeld (1982) proposed residuals for use with a fitted proportional hazards model and 
packages providing them refer to as the “Schoenfeld residuals”, which are based on the 
individual contributions to the derivative of the log partial likelihood. It is obtained by taking the 
first derivative of the log of the partial likelihood function for the 𝑘𝑡ℎcovariate as follows: 
𝜕𝐿𝑃(𝛽)
𝜕𝛽𝑘
   = ∑ {𝑋𝑖𝑘 −
∑ 𝑋𝑗𝑘𝑒
𝑿𝒋
′𝜷
𝑗𝜖𝑅(𝑡𝑖)
∑ 𝑒
𝑿𝒋
′𝜷
𝑗𝜖𝑅(𝑡𝑖)
}𝑛𝑖=1 = ∑ {𝑋𝑖𝑘 − ?̅?𝑤𝑖𝑘}
𝑛
𝑖=1 ………(3.31) 
Where ?̅?𝑤𝑖𝑘 =
∑ 𝑋𝑗𝑘𝑒
𝑿𝒋
′?̂?
𝑗𝜖𝑅(𝑡𝑖)
∑ 𝑒
𝑿𝒋
′?̂?
𝑗𝜖𝑅(𝑡𝑖)
 
The estimator of the Schoenfeld residual for the 𝑖𝑡ℎindividual on the 𝑘𝑡ℎcovariate is obtained 
from (3.30) by substituting the partial likelihood estimator of the coefficient, ?̂? and is 
?̂?𝒔𝒊𝒌 = 𝛿𝑖(𝑋𝑖𝑘 − ?̅̂?𝑤𝑖𝑘)……………… . .………………………(3.32) 
Where  ?̅̂?𝑤𝑖𝑘 =
∑ 𝑋𝑗𝑘𝑒
𝑿𝒋
′?̂?
𝑗𝜖𝑅(𝑡𝑖)
∑ 𝑒
𝑿𝒋
′?̂?
𝑗𝜖𝑅(𝑡𝑖)
 is the estimator of the risk set conditional mean of the 
covariate. 
Since the partial likelihood estimator of the coefficient, ?̂? is the solution to the equations 
obtained by setting (33) equal to zero, the sum of the Schoenfeld residuals is zero. 
It is suggested that (Grambsch and Therneau, 1994) scaling the Schoenfeld residuals by an 
estimator of its variance yields a residual with greater diagnostic power than the un-scaled one. 
Let the vector of p Schoenfeld residuals for the 𝑖𝑡ℎsubject be denoted as 
?̂?𝑠𝑖𝑘
′ = (?̂?𝑠𝑖1, ?̂?𝑠𝑖2, … , ?̂?𝑠𝑖𝑝)………………….(3.33) 
Where ?̂?𝑠𝑖𝑘 is the estimator in (31), with the convention that 𝑟𝑠𝑖𝑘 = 𝑚𝑖𝑠𝑠𝑖𝑛𝑔 𝛿𝑖 = 0. 
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Thus, the vector of scaled Schoenfeld residuals is given as the product of the inverse of the 
covariance matrix and the vector of residuals; 
?̂?𝑖
∗ = [?̂?𝑎𝑟(?̂?𝑖)]
−1
?̂?𝑖 , …………………….(3.34) 
Where ?̂?𝑎𝑟(?̂?𝑖) is the estimator of the 𝑝 × 𝑝 covariance matrix of the vector of residuals for the 
𝑖𝑡ℎ  subject. 
However, Grambsch and Therneau suggested based on their experience that the matrix, 
?̂?𝑎𝑟(?̂?𝑖), tends to be fairly constant, the use of an easily computed approximation for the scaled 
Schoenfeld residuals.(45) If this matrix is constant, its inverse may be approximated by 
multiplying 
the estimator of the covariance matrix of the estimated coefficients by the number of events (in 
our study number of death m). That is 
 [?̂?𝑎𝑟(?̂?𝑖)]
−1
= 𝑚?̂?𝑎𝑟(?̂?)………………(3.35) 
Consequently, the approximate scaled Schoenfeld residuals are obtained by substitution as 
?̂?𝑖
∗ =  𝑚?̂?𝑎𝑟(?̂?)?̂?𝑖 ……………………(3.36) 
Each of these residuals provides a useful tool for examining one or more aspects of model 
adequacy. 
Now, we are going to assess the adequacy of a model by considering these issues, namely testing 
for linearity of continuous covariates, checking model assumption, looking for outliers and 
testing the goodness of fit of the model. 
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3.3.6.2. Testing for Linearity of Covariates 
After identifying a particular set of explanatory variables on which the hazard function depends, 
it is important to check that the correct functional form has been adopted for the continuous 
covariates. An improvement for the fit of a model may be obtained by using some transformation 
of the values of a variable instead of the original one. The plot of martingale residuals obtained 
from fitting the model, excluding the covariate whose functional form needs to be determined, 
against the excluded covariate display the functional form required for the covariate. LOESS 
smoothed curve can be superimposed on the scatter plots to give interpretation. If the functional 
form suggested (observed) in using the above plots has some pattern, which is non-linear, the 
covariate can be so transformed and the martingale residuals again should be plotted against the 
transformed covariate. A straight line would then confirm that the appropriate transformation has 
been used to the covariate. 
3.3.6.3. Checking the Assumption of Proportional Hazards 
In order to use the Cox model, we must check the assumption of whether the effects of covariates 
on hazard ratio remain constant over time. This is a critical assumption of proportional hazards 
model and must be checked for each covariate. 
Different studies suggest that several tests and graphical techniques can be used to assess 
proportionality assumptions in fitting the Cox model. The Grambsch-Therneau test of non-
proportionality uses partial residuals for the test of proportional hazards assumption. In order to 
use this test for the 𝑖𝑡ℎ covariate Grambsch and Therneau (1994) propose a time-varying 
coefficient as  
𝛽𝑖(𝑡) = 𝛽𝑖 + 𝛾𝑖𝑔𝑖(𝑡)………………… . . (3.37) 
Where 𝛽𝑖(𝑡) is time varying coefficient, 𝛽𝑖 is constant, 𝑔𝑖(𝑡) is some specified function of time, 
usually 𝑔𝑖(𝑡)  =  𝑙𝑛(𝑡).  
The Cox proportional hazard model for time varying coefficient with 𝑔𝑖(𝑡)  =  𝑙𝑛(𝑡) becomes 
ℎ[𝑡, 𝑋𝑖, 𝛽𝑖(𝑡)]  = ℎ0(𝑡)𝑒𝑥𝑝[𝛽𝑖(𝑡)𝑋] , …………………(3.38) 
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Substitute 𝛽𝑖(𝑡)  = 𝛽𝑖 + 𝛾𝑖𝑔𝑖(𝑡) in equation (3.38) gives 
ℎ[𝑡, 𝑋𝑖, 𝛽𝑖(𝑡)]  = ℎ0(𝑡)𝑒𝑥𝑝{𝛽𝑖𝑋 + 𝛾𝑖 ln(𝑡)𝑋}……… (3.39) 
This looks like the proportional hazards model where the interaction term, (𝑡) is included in the 
model in addition to the main effect 𝑋𝑖. To test the significance of the interaction term 𝑋𝑖𝑙𝑛(𝑡) ,  
That is:  
                                      𝐇𝟎: 𝜸𝒊 = 𝟎     Against 
                                 𝐇𝟏: 𝜸𝒊 ≠ 0       for i=1, 2,…, p.  
We can use likelihood-based tests like Wald test. That is 
𝒁 =
𝜸𝒊
𝑆𝐸(𝜸𝒊)
……………………(3.40) 
Which follows a standard normal distribution.  
 
The test rule used is: 
 The coefficient of the 𝑗𝑡ℎ covariate is not time dependent if  𝑍 < 𝑍𝛼/2 i.e. do not reject 
𝐻0. That is, model assumption is satisfied. 
 The coefficient of the 𝑗𝑡ℎ covariate is time dependent if 𝑍 > 𝑍𝛼/2 i.e. reject 𝐻0. That is, 
model assumption is not met. 
If 𝜸𝒊  =  0 is not rejected, 𝛽𝑖’𝑠 are not time varying coefficients and hence the proportional 
hazards assumption is satisfied. If 𝜸𝒊  =  0 is rejected then the proportional hazards assumption is 
not satisfied and we have to look for another model. 
The Schoenfeld residuals graphical technique can also be used to assess Cox model assumptions. 
The technique is based on individual contributions to the log-partial likelihood and measures the 
difference between the covariate for the 𝑖𝑡ℎ individual and a weighted average of the covariate 
over the risk set at the time the 𝑖𝑡ℎ individual event [44]. 
 For greater diagnostic power the scaled Schoenfeld residuals are considered, the scaling can be 
done on the variance of the 𝑖𝑡ℎ subject Schoenfeld residuals. 
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To check the proportionality assumption for each covariate, we plot the scaled Schoenfeld 
residuals on the 𝑌 −axis against log of survival time on the 𝑋 −axis. If the proportional hazards 
assumption is satisfied, the distribution of residuals over time is random, that is, does not show a 
particular trend, and the smoothed plot called Locally Weighted polynomial regression 
(LOWESS) line summarizing the residuals should be a straight line and close to the horizontal 
reference line. Otherwise, a plot of scaled Schoenfeld residuals for a given covariate may reveal 
a violation of the proportional hazards assumption [44]. 
3.3.6.4. Identification of Influential Subjects 
Another important aspect of the model evaluation is a thorough examination of regression 
diagnostic statistic to identify which, if any, observation have an undue influence on the fit of the 
model. It is important to determine whether the hazard ratio will be affected to a large extent by 
any one individual observation’s data in the model. We do this by fitting the model for all n 
observations in the data set and then refit the same model to the sets of n-1 observations obtained 
by omitting each of the n observations one at a time. Whenever an observation can exert unusual 
influence on the hazard ratio, this will be noticeable in significant change in the parameter 
estimate(s) while removing the observation’s data from the data set and refit the same model. 
That is we can use ∆𝑖?̂?𝑗 = (?̂?𝑗 − ?̂?𝑗(−𝑖)) which is known as delta-beta [39], as the statistic to 
detect an outlier observation of the data. 
The change in the parameter estimate is large for an outlier observation while the delta-beta is 
not large for others. And we measure the influence of each observation on the estimated 
regression coefficients. To examine the influence of a 𝑗𝑡ℎcovariate value of the 𝑖𝑡ℎ individual on 
the 𝑗𝑡ℎ  regression coefficient estimate we use delta-beta statistics 
∆𝑖?̂?𝑗 = (?̂?𝑗 − ?̂?𝑗(−𝑖))……………………………… . . (3.41) 
Where ?̂?𝑗  is the 𝑗
𝑡ℎ
 coefficient based on 𝑛 observations and ?̂?𝑗(−𝑖) is the 𝑗
𝑡ℎcoefficient based on 
𝑛 − 1 observations (𝑖𝑡ℎ observation is deleted). 
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The overall summary statistic of the influence of a subject on the estimator of all the coefficients 
may be approximated using the likelihood displacement statistic 𝑙𝑑𝑖. The statistics 𝑙𝑑𝑖 is an 
approximation to the amount of change in log partial likelihood when the 𝑖𝑡ℎ subject is deleted. 
In this context the statistic is called the likelihood displacement statistic. It can be shown that 
𝑙𝑑𝑖 =  2[𝑙𝑝(?̂?) –  𝑙𝑝(?̂?(−𝑖))]  
The next step in the modeling process is to identify explicitly the subjects with the extreme 
values, refit the model deleting these subjects. The final decision on the continued use of a 
subject’s data to fit the model will depend on the observed percentage change in the coefficients 
that result from deleting the subject’s data and, more importantly, the clinical plausibility of that 
subject’s data [40]. 
3.3.7. Assessing the Goodness of Fit of the Model 
In practice, models may not exactly represent the true relationship between the response variable 
(survival time of HIV-infected children after ART) with different covariates. Hence, we should 
apply a mechanism by which we could assess the goodness of fit of the model what we have 
chosen.  
Since the Cox-proportional hazards regression model is one of the models to be used for 
description and inference about the effects of predictors on the survival time of HIV-infected 
children after ART initiation, no one could feel satisfied that a particular model of a given form 
is the only model that best explains reality. Thus we have to assess the goodness of fit of the 
selected model. 
The first step in assessing the fitted model is checking the overall goodness of fit of the model to 
the observed data. To test the overall goodness of fit of the model we used partial likelihood ratio 
test. We test  
                       𝐻0: 𝜷 =  0   Against 
                      𝐻1: 𝑁𝑜𝑡 𝐻0     at a specified α-level of significance. 
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The test statistic for this purpose is 
𝑮 = 2[𝑙𝑝(?̂?) − 𝑙𝑝(0)]…………… . . (3.42) 
Under the null hypothesis this follows a chi-square distribution with k-1 degrees of freedom. 
We decide that the model does not have ‘good fit’ if the computed value of 𝑮 based on the 
available data is less than 𝒙(𝒌−𝒑)
𝟐 . And we decide to reject the null hypothesis and decide that 
the model has ‘good fit’ if the computed value of 𝑮 based on the available data is greater than or 
equal to   𝒙(𝒌−𝒑)
𝟐
, where p is the number of significant covariates. 
To test the significance of individual parameter coefficients we used Wald test statistic. We test                                       
                           H0: ?̂?𝒍 = 0     Against       
                           H1: 𝑁𝑜𝑡 𝐻0         at α-level of significance.  
The test statistics used in this case are 
𝒁 =
?̂?𝒍
𝑆.𝐸(?̂?𝒍)
 ………………… . .. (3.43) 
Under the null hypothesis this follows a standard normal distribution. We decide the 𝑙𝑡ℎcovariate 
is not significant if the computed value of 𝑍 based on the available data is 𝑙𝑒𝑠𝑠 𝑡ℎ𝑎𝑛  𝒁(𝜶/𝟐) and 
we do not reject 𝐻0. Whereas we decide to reject the null hypothesis H0 and consider the 
𝑙𝑡ℎcovariate if the computed value of 𝑍 based on the available data is 𝑔𝑟𝑒𝑎𝑡𝑒𝑟 𝑡ℎ𝑎𝑛  𝒁(𝜶/𝟐). 
3.3.8. Interpretation of the Regression Coefficients 
For categorical covariates with k-levels, we apply categorical variable coding with k-1 dummy 
variables and one reference level against which all other levels are compared. The comparison is 
made by taking the ratio of the hazard function of HIV infected children in each dummy variable 
to the hazard function of children in the reference group. The resulting hazard ratio 𝒆𝜷 compares 
the rate of deaths of children in each group to deaths of children in the reference group.  
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The regression coefficient 𝜷 is therefore, interpreted as: at any time during the study period the 
logarithm of the hazard ratio of HIV- infected children with covariate value in a defined dummy 
variable to HIV- infected children with covariate value equals to zero (reference category) is 𝛽, 
given that all other variables in the model are the same. 
For continuous covariate the regression coefficient 𝜷 is interpreted as the change in the log 
hazard of death of children for a unit change of a continuous covariate provided that the log 
hazard ratio is linear with the covariate of interest and all other factors are kept constant. Hence, 
we should test for linearity of log hazard ratio against the continuous covariates in the model.  
To test the linearity of log hazard ratio against a continuous covariate, we use the plots of 
martingale residual. If the plots of the martingale residuals are randomly distributed with no 
systematic pattern, about a horizontal straight line through zero after excluding the continuous 
covariate for which we are checking the linearity assumption then the log hazard ratio is linear. If 
the covariate is not linear then it requires transformation. 
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CHAPTER FOUR 
4. Statistical Data Analysis and Discussion 
4.1 Introduction 
The results of the study are discussed in this chapter. The response variable, survival time of 
HIV-infected children after starting ART, is continuous. The censoring indicator (status) is 0 for 
censored observations and 1 for event, in our case death. In this study, Cox survival regression 
model is used to see the relationship between the proposed independent variables and the 
response variable. We start our data analysis by giving the summary statistics for the categorical 
variables considered in the study; we then proceed to the bivariate analysis, checking 
assumptions and fitting the final model in multivariate analysis. Then, the adequacy of the model 
is investigated. Finally, the results are discussed and interpreted. 
4.2 Summary Statistics 
The data used in the study were based on secondary data from hospital records which consists of 
269 HIV infected children aged below 15 years who started ART between 2008 and 2013 were 
included and followed until April 2015 in Gondar University teaching Hospital. The patients 
were followed up for a median of 55 months and the minimum follow up time was 20 month and 
the maximum was 91 months.  
A total of 269 participants with full record of variables were included in the study, from this 46 
(17.1%) children died due to the disease, 223 (82.9%) were dead and loss to follow-up during the 
time of data collection. Out of the total 269 ART followers, 116 (36.65%) were male and the rest 
were females. Among 269 children, 78 (30%) were at clinical stage IV, 82 (30.5%) were at 
clinical stage III, 63 (23.4%) were at clinical stage II and the rest 46 (17.1%) were at clinical 
stage I when they started ART. And there were 142 (52.8%) patients who were able to work, 68 
(25.3%) were ambulatory and 59 (21.9%) were bedridden. (See Table 4.1 Appendix: A) 
 
Both continuous and categorical baseline covariates are included in the analyses. The average 
baseline weights of the patients are 14.5 kilograms (with a standard deviation of 7.43 kilograms).  
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4.3 Descriptive Analysis 
It is vital to do some basic descriptive analysis that will be used as initiation to our subsequent 
finding. We start with the test of whether the observed differences in data summary among 
different factors are statistically significant or not. We use log-rank test and Kaplan-Meier 
survival estimates to look into the significance of the difference among different factors of HIV 
infected children. 
Log-rank test was performed to investigate the significance of the observed difference in the 
Kaplan-Meier estimates of the survivor functions among different categories of the factors. 
The log-rank test is used at 5% level of significance to validate the differences in the survival 
time of each factor. The null hypothesis to be tested claims, that there is no difference between 
the probabilities of an event (death) occurring at any time point.  
The continuous covariates age, baseline hemoglobin level and CD4 count of children were 
categorized into clinically meaningful groups so that it would be simple to describe and interpret 
the results. But weight and total lymphocyte counts left as continuous, because these variables 
were founded that non-significant in categorized form. So, these variables are used as continues 
to check their significances. The output from computer is summarized in Table 4.2 Appendix: A. 
 
Figure 4.1: Plot of the overall estimate of Kaplan-Meier survivor function 
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The graph was plotted between estimated survival probabilities/estimated survival probability 
(on Y axis) and time past after entry into the study (on X axis) consists of horizontal and vertical 
lines. The survival curve is drawn as a step function: the probability of surviving remains 
unchanged between the events, even if there are some intermediate censored observations. 
The Log-rank test was performed to investigate the significance of the observed difference in the 
Kaplan-Meier estimates of the survivor functions among different categories of the factors. This 
means there is difference in survival experience between two or more levels of the factors. The 
result obtained from Table 4.2 the p-value of the Log-rank test points out the following results. 
Table 4.3: Log rank test for equality of survival time of HIV infected children among different 
groups of covariates. 
Group Chi-square Df 𝑷𝒓 > Chi-square 
Age 8.040 2 0.018 
Gender 1.787 1 0.281 
Baseline Functional Status 9.178 2 0.010 
Baseline WHO Stage 37.220 3 0.000 
Baseline CD4 Count 19.493 1 0.000 
Original   Regimen 2.345 4 0.673 
Reason For ART 4.906 3 0.379 
Prophylaxis use 0.193 1 0.660 
Baseline TB Screen 0.239 1 0.625 
Opportunistic Illness 0.414 1 0.520 
Baseline Hemoglobin level  10.091 3 0.018 
 
According to the result of log-rank test in Table 4.3, there was no significant difference in 
survival experience between the various categories of gender, opportunistic illness, baseline TB 
status, reasons for ART, original regimen and Prophylaxis use. However, the p-values of the log-
rank test showed that the survival experience of patients in different categories of baseline 
functional status, baseline CD4 count, baseline WHO clinical stage of disease at initiation of 
treatment and baseline hemoglobin level are those variables which have statistically significant 
difference in experiencing an event (death). These significant covariates can also be presented 
graphically in Appendix B using Keplan-Meire curves. 
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The survival curves in the Appendix: B had a clear difference in the way they lay. In Appendix: 
B Figure 4.2.a shows that age groups less than 1.5 years had lower survival rate than for those 
age groups 1.5-5 years and 5 to 1 years. A plot of Keplan-Meire survival estimates of functional 
status shows those children whose functional status workings have a better survival rate than 
ambulatory and bedridden. Figure 4.2.c in Appendix: B also supports that there is a difference in 
survival function between WHO clinical stages I, II, III and IV. In general, WHO clinical stage 
IV survives much lower than stage I, stage II and stage III. Again the Figure 4.2.d in the 
Appendix: B also supports that there is a difference in survival function of baseline CD4 counts 
and further shows that CD4 counts above the threshold level survives better than CD4 counts 
below the threshold levels. Similarly in Figure 4.2.e in Appendix: B supports that higher 
hemoglobin group (non-anemic groups) survives better than anemic groups (i.e. hemoglobin 
level <10gm/dl). 
4.4 Bivariate Analysis of Survival Time with Different Explanatory Variables 
In this section, a bivariate analysis of the association between survival time and all covariates 
will be done. For categorical covariates, the analysis includes Kaplan-Meier estimates of the 
group specific survivorship functions, point and interval estimates of the mean survival time and 
Log-Rank significance tests to compare survival time across the groups defined by the variable 
used. Continuous covariates like age, baseline CD4 count and baseline hemoglobin level were 
treated as categorical covariates based on the groups we have previously explained. But the other 
covariates like weight and total lymphocyte counts are treated as continuous as it is. 
For each covariate we will use a bivariate Cox proportional hazards model analysis that contains 
a single independent variable in order to have an idea about each covariate. Likelihood ratio chi-
square test is used to test the significance of bivariate relationship. Covariates are selected based 
on their contribution to reduce the log partial likelihood function (-2LL) for the purpose of 
further investigation in the multivariable Cox proportional hazards model.  
In bivariate analysis, using likelihood ratio chi-square test, the variables that are found to be 
significant (p-value 0.25 is used as a criterion for significance) are Age of a patient (age), initial 
weight, baseline functional status, baseline CD4 count, baseline WHO stage and baseline 
hemoglobin level.  
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Age, weight, baseline functional status, baseline CD4 count, baseline WHO stage and baseline 
hemoglobin level, with p-value less than 0.25, have relatively strong associations to the death of 
HIV infected children. Table 4.4 summarizes the findings of bivariate analysis as follows: 
Table 4.4: Summary statistics of single covariate analysis of Cox proportional hazards model of 
survival time of HIV infected children after imitation of ART at Gondar University Hospital. 
Variable DF 
Parameter 
Estimate 
(B) 
Std. 
Error 
Wald 
Pr>Chi-
Sq. sig. 
Hazard 
Ratio 
95.0% CI for 
Exp(B) -2 log 
likelihod 
Reduction 
in -2LL 
due to the 
inclusion 
Lower Upper 
Weight 1 -0.029 0.022 1.799 0.180 0.971 0.930 1.014 487.401 1.880 
Age 
Age(1) 
Age(2) 
2 
1 
1 
 
1.031 
0.726 
 
0.418 
0.332 
7.536 
6.100 
4.778 
0.023 
0.014 
0.029 
 
2.804 
2.066 
 
1.237 
1.078 
 
6.357 
3.959 
481.530 7.751 
Gender 1 -0.391 0.295 1.758 0.251 1.479 0.829 2.638 487.524 1.757 
Prophylaxis taken 1 -0.147 0.336 0.192 0.661 0.863 0.447 1.668 489.085 0.196 
BaselineTBScreen 1 0.145 0.298 0.238 0.626 1.156 0.645 2.074 489.042 0.239 
Opportunistic illness 1 0.190 0.296 0.412 0.521 1.209 0.677 2.160 488.871 0.41 
Total lymphocytes 1 0.017 0.010 2.520 0.265 1.017 0.996 1.038 486.717 2.564 
BaselineCD4Count 1 -1.498 0.372 16.196 0.000 0.224 0.108 0.464 468.634 20.647 
BaselineWHOStage 
BaselineWHOStage(1) 
BaselineWHOStage(2) 
BaselineWHOStage(3) 
3 
1 
1 
1 
 
-2.259 
-2.215 
-1.193 
 
0.730 
0.606 
0.353 
27.734 
9.567 
13.373 
11.434 
0.000 
0.002 
0.000 
0.001 
 
0.104 
0.109 
0.303 
 
0.025 
0.033 
0.152 
 
0.437 
0.358 
0.606 
 
455.274 
 
34.007 
FunctionalStatus 
FunctionalStatus(1) 
FunctionalStatus(2) 
2 
1 
1 
 
-0.930 
-0.790 
 
0.334 
0.395 
8.573 
7.749 
4.007 
0.014 
0.005 
0.045 
 
0.365 
0.454 
 
0.205 
0.209 
 
0.760 
0.984 
481.397 
7.884 
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Note: Beginning Block, initial Log Likelihood function: -2 Log likelihood: 489.281 
It is not feasible to calculate a Kaplan-Meier curve for the continuous predictors since there 
would be a curve for each level of the predictor and a continuous predictor simply has too many 
different levels. Instead we consider the Cox proportional hazard model with a single continuous 
predictor. Instead we consider the Chi-squared test for weight and total lymphocyte count, which 
have a p-value of 0.180 and 0.265, respectively. Thus, the variable weight is a potential 
candidate for the next step since its p-value is less than the cut of value of 0.25. 
4.6. Multivariate Analysis 
One problem with any bivariate analysis is that it ignores the possibility that a collection of 
covariates, each of which is weakly associated with the outcome, may have a significant effect 
when used together with other covariates in the model. If this is thought to be a possibility, then 
we should choose a significance level large enough to allow the suspected variables to become 
candidates for inclusion in the multivariate model. It is for this reason that we use p-value of 0.25 
for selection of variables that are potentially candidates for the multivariate analysis from 
bivariate findings and those significant interactions on partial likelihood ratio test.  
OriginalRegimen 
OriginalRegimen(1) 
OriginalRegimen(2) 
OriginalRegimen(3) 
OriginalRegimen(4) 
4 
1 
1 
1 
1 
 
.349 
1.030 
.325 
.847 
 
.745 
.913 
.745 
.914 
2.254 
.220 
1.272 
.190 
.860 
0.689 
0.639 
0.259 
0.663 
0.354 
 
1.418 
2.801 
1.384 
2.333 
 
.329 
.468 
.321 
.389 
 
6.108 
16.777 
5.960 
13.979 
 
487.286 
 
1.995 
 
 
ReasonForART 
ReasonForART(1) 
ReasonForART(2) 
ReasonForART(3) 
 
 
3 
1 
1 
1 
 
 
-.384 
-.079 
-.890 
 
 
.659 
.375 
.475 
 
 
4.633 
.339 
.044 
3.519 
 
 
0.201 
0.560 
0.833 
0.061 
 
 
0.681 
0.924 
0.410 
 
 
.187 
.444 
.162 
 
 
2.480 
1.926 
1.041 
 
 
483.931 
 
 
5.35 
BaselineHemoglobin 
BaselineHemoglobin(1) 
BaselineHemoglobin(2) 
BaselineHemoglobin(3) 
3 
1 
1 
1 
 
1.332 
1.511 
1.084 
 
0.498 
0.539 
0.558 
8.736 
7.163 
7.849 
3.771 
0.033 
0.007 
0.005 
0.052 
 
3.789 
4.533 
2.955 
 
1.428 
1.575 
0.990 
 
10.052 
13.051 
8.820 
477.660 11.621 
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This means we include age, initial weight, hemoglobin group, baseline CD4 count, WHO clinical 
stage and functional status in our model. Multivariable Cox proportional hazards regression 
model using the response variable, namely survival time of HIV infected children after initiation 
of ART, with censoring indicator variable along with the covariates was analyzed using the 
statistical package SPSS and STATA software’s. The results of the multiple covariates Cox 
proportional hazards model are displayed in Table 4.6 below. 
Table 4.6: Results of the multivariable Cox Proportional Hazards regression model containing 
the variables significant at 20 - 25% level in the univariable proportional hazards Cox regression 
model of HIV infected children under ART.  
Variables in the Equation 
 B SE Wald df Sig. Exp(B) 95.0% CI for Exp(B) 
Lower Upper 
Age   6.627 2 .036    
Age(1) 1.305 .613 4.539 1 .033 3.689 1.110 12.261 
Age(2) 1.028 .421 5.970 1 .015 2.796 1.226 6.377 
BaselineFunctionalStatus   1.889 2 .389    
BaselineFunctionalStatus(1) -.410 .369 1.240 1 .265 .663 .322 1.366 
BaselineFunctionalStatus(2) -.539 .432 1.556 1 .212 .583 .250 1.361 
BaselineWeight .022 .029 .582 1 .445 1.022 .966 1.082 
BaselineWHOStage   23.084 3 .000    
BaselineWHOStage(1) -2.393 .748 10.251 1 .001 .091 .021 .395 
BaselineWHOStage(2) -1.896 .623 9.275 1 .002 .150 .044 .509 
BaselineWHOStage(3) -1.098 .369 8.861 1 .003 .334 .162 .687 
BaselineCD4Count -1.727 .395 19.082 1 .000 .178 .082 .386 
BaselineHemoglobin   11.111 3 .011    
BaselineHemoglobin(1) 1.688 .525 10.338 1 .001 5.411 1.933 15.146 
BaselineHemoglobin(2) 1.670 .565 8.750 1 .003 5.314 1.757 16.070 
BaselineHemoglobin(3) 1.554 .616 6.364 1 .012 4.731 1.414 15.826 
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The variable that was found to be insignificant at 5% level of significance in multivariate 
analysis is initial weight and baseline functional status. We drop these variables for the next step 
and perform a multivariate analysis for the remaining four covariates. The following table shows 
the fitted Cox-proportional hazards model for covariates age, baseline hemoglobin level, baseline 
CD4counts and baseline WHO clinical stages.   
From Table 4.6, the result revealed that the log partial likelihood function (-2LL) with covariates 
that are significant in bivariate analysis was 408.402. The variable, functional status is the first 
variable to be removed from the model, the log partial likelihood function (-2LL) become 
410.251. When this variable was removed as it caused an increase in -2LL of only 1.849 with P-
value=0.389. Similarly, initial weight is the other variable to be removed from the model, when 
this variable was removed the log partial likelihood function (-2LL) becomes 408.982. So, the 
removal of this variable caused an increase in -2LL of only 0.58 with P-value=0.445. We 
computed the percentage change in the coefficients remained in the model as a result of deletion 
of a covariate from the model in Table 4.7 below. And no significant change (5%) in any one of 
the remaining coefficients in the model was seen. The model containing the variables that were 
significant in the previous step and a model which eliminated one variable at a time, all the 
changes are found to be significant. 
Table 4.7: Multivariate analysis using the significant variables in the above steps. 
Variables in the Equation 
 B SE Wald df Sig. Exp(B) 95.0% CI for 
Exp(B) 
Lower Upper 
Age   11.257 2 0.004    
Age(1) 1.278 0.466 7.513 1 0.006 3.590 1.439 8.953 
Age(2) 0.968 0.341 8.077 1 0.004 2.632 1.350 5.130 
BaselineWHOStage   24.502 3 0.000    
BaselineWHOStage(1) -2.443 0.744 10.794 1 0.001 0.087 0.020 0.373 
BaselineWHOStage(2) -1.890 0.623 9.192 1 0.002 0.151 0.045 0.513 
BaselineWHOStage(3) -1.179 0.366 10.370 1 0.001 0.308 0.150 0.630 
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BaselineCD4Count -1.713 0.391 19.200 1 0.000 0.180 0.084 0.388 
BaselineHemoglobin   13.658 3 0.003    
BaselineHemoglobin(1) 1.838 0.507 13.158 1 0.000 6.286 2.328 16.973 
BaselineHemoglobin(2) 1.721 0.550 9.795 1 0.002 5.592 1.903 16.436 
BaselineHemoglobin(3) 1.633 0.600 7.406 1 0.007 5.119 1.579 16.593 
 
Here all covariates are significant at 5% level of significance. Thus, it becomes a preliminary 
final model after linearity of continuous covariates is checked. Therefore, the covariates, age, 
hemoglobin level, baseline CD4 count and WHO clinical stage remain in the model at this stage. 
In this study we also considered all possible interactions of order two, the interactions of 
hemoglobin group with levels of WHO clinical stages, hemoglobin group with age and baseline 
CD4 counts, age with levels of WHO clinical stages and baseline CD4 counts, and CD4 counts 
with levels of WHO clinical stages. We then fitted a Cox proportional hazards model containing 
the four covariates and one interaction term at a time.  
To test the significance of the regression coefficient of an interaction term, Log-rank test statistic 
was used. As we observed in Table 4.8 Appendix: B, no coefficient of interaction terms of order 
two were found significant at 5% significant levels. From this result we can observe that the 
interaction terms are not significant and will not be included in the model. Therefore, we 
consider the final model which contains the main effects only, i.e. age, baseline hemoglobin 
level, baseline CD4 counts and WHO clinical stages. Since all the significant covariates were 
categorical covariates, so no need of checking for the linearity of continuous variables.  
We have now completed the model development stage that involves the three basic activities, 
namely selection of covariates, checking for the linearity of continuous covariates in the model 
and the issue of interaction, and we can begin the second task of assessing the model adequacy. 
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4.7. Model Diagnostics 
In our survival regression analysis assessment of model adequacy we must i) test the assumption 
of proportional hazards ii) check influence and poorly fit subjects and iii) overall summary 
measures of goodness of fit.  
4.7.1. Checking the Proportionality of Covariates in the Model 
One of the main assumptions of the Cox proportional hazard model is proportionality. There are 
several methods for verifying that a model satisfies the assumption of proportionality. We will 
check proportionality by including time-dependent covariates in the model by using the time 
varying coefficient (tvc).  
Time dependent covariates are interactions of the predictors and time. In this analysis we choose 
to use the interactions with 𝑙𝑜𝑔(𝑡𝑖𝑚𝑒) because this is the most common function of time used in 
time-dependent covariates but any function of time could be used. If a time-dependent covariate 
is significant this indicates a violation of the proportionality assumption for that specific 
predictor. 
The conclusion is that all of the time-dependent variables in Table 4.9 and Table 4.10 in 
Appendix: B is not significant either collectively or individually thus supporting the assumption 
of proportional hazard.           
Another method of testing the proportionality assumption is by using graphical diagnoses of 
scaled Schoenfeld residuals. Under the assumption of proportionality of the proportional hazards 
model, the distribution of residuals over time is random and LOWESS smoothing line should be 
a straight line around zero. If the lines in these plots in are parallel then we have further 
indication that the predictors do not violate the proportionality assumption. (See the plots of 
scaled Schoenfeld residuals in Appendix: C) 
4.7.2. Assessing the Goodness of Fit of the Model 
We also need to check the goodness of fit of the proportional hazards model based on the 
empirical data. Therefore, for the model fitted in this study the Likelihood Ratio, score and Wald 
tests are used to compare (at 5% significance level) the goodness of fit of the model.  
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The SAS output in Table 4.11 reveal that the log partial likelihood function (-2LL) without 
covariate was 489.281 while the function with significant covariates was 410.634. This result 
shows that the model is appropriate with chi-square of 78.647 with 9 degrees of freedom and p-
value <0.0001. 
 
Table 4.11 Likelihood ratio, Score and Wald tests for testing the global null hypothesis of 𝜷 = 𝟎. 
   Testing Global Null Hypothesis: 𝛽 = 0 
Test Chi-Square Df       Pr>Chisq 
Likelihood Ratio 78.647 9 <0.0001 
Score 74.786 9 <0.0001 
Wald  67.759           9 <0.0001 
Moreover, Cox-Snell residuals are used to assess the overall goodness of fit of the model. The 
plot in Figure 4.3 of the cumulative hazard function of the Cox-Snell residual against the Cox-
Snell residuals are fairly close to the 45
o
 straight line through the origin. This suggests that the 
model fit to the data is satisfactory. 
 
The 45o-striaght line through the origin is drawn for reference line. 
Figure 4.3: Cumulative hazard plot of the Cox-Snell residuals of the Cox proportional hazards 
regression model 
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4.7.3. Assessing for Influential Observations 
At this step of model examination, we look for the existence of leverage observations that have 
illegitimate impact on inferences made on the basis of model fitted to an observed set of survival 
data. Leverages, similar to what is obtained in linear and logistic regression, are also adapted into 
proportional hazards regression through the DFBETA to examine if there are subjects with 
undue influence on the fit. As a result, the DFBETA is employed to examine if there is 
disproportionate influence of an observation on the parameter estimate in the fitted Cox 
regression model [37 and 39]. 
The first five largest changes in parameter estimates are shown in Table 4.12 of the Appendix: C. 
To begin with the largest difference for covariate age less than 1.5 years was observed for patient 
numbered 25. The result reveals that the change in the parameter estimate if the data for this 
patient is discarded is 0.1555451. Obviously, the omission of this patient increases the hazard 
rate in relation to the baseline hazard rate. However, the question to be posed is whether the 
increment in the hazard rate is striking or not. The same can be judged by taking standard error 
of the parameter estimate of age of patients (0.466) in the full data set into account. That is the 
percentage change in parameter estimate if the observation is removed is about 33.4% of the 
standard error (i.e. less than one standard error). Thus, removing this observation cannot bring a 
significant change on survival time of HIV infected children. 
When the data on the 77
th
 child is deleted, the estimated coefficient for CD4 count above 
threshold has shown the largest difference. The deletion decreased the hazard ratio, but the 
percentage change in the estimate is not much (33.7%), which is less than one standard error, to 
delete the observation from the analysis. Therefore, we do not eliminate the data of the 
hemoglobin level of this child as an influential outlier observation. 
Moreover, the maximum change in the parameter estimates were also found for patient 
numbered 215 in hemoglobin level category 7-8.5gm/dl. If this observation is removed the 
percentage change in parameter estimate is 42.5% of their respective standard error. Thus, 
deleting the observations of the highest difference in parameter estimates had no significant 
impact on the parameters of the covariates and on the fit of the model.  
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We had examined also the impact of an observation on the overall estimated coefficients of the 
model using the likelihood displacement statistic 𝒍𝒅𝒊. The statistics 𝒍𝒅𝒊 is an approximation to 
the amount of change in log partial likelihood when the 𝑖𝑡ℎ subject is deleted. The maximum 
value of the 𝒍𝒅𝒊 is 0.664 from deletion of the 215
th
 subject. But the change is not much 
considerable. Therefore, it can be concluded that there is no influential outlier observation in the 
data set that illegitimately inflate the estimates of the parameters of the covariates in the final 
model. 
4.8. Interpretation and Discussion of Results 
4.8.1 Interpretation of the Results 
When the multivariate proportional hazards Cox model is used in the analysis of survival data, 
the coefficient of a categorical explanatory variable in the model can be interpreted as the 
logarithm of the ratio of the hazard of death to the baseline (reference group) hazard. On the 
other hand, the coefficient for a continuous explanatory variable is the estimated change in the 
logarithm of the hazard ratio for a unit increase in the value of the explanatory variable after 
adjustment for the remaining variables in the model. Thus, the interpretation of those variables 
that were significant in the final proportional hazards model of HIV infected children patients 
treated with ART in Gondar University hospital is as follows. 
Age, WHO clinical stages, CD4 counts and hemoglobin level are the four categorical variables 
that are found to be significantly associated with the survival time of HIV infected children 
under ATR treatment in the fitted Cox regression model. Let us begin with baseline CD4 cell 
count of the patient that is supposed to be significant both clinically and statistically. In this 
study, a baseline CD4 cell count has been found to have a significant impact on the survival time 
of HIV infected children. The estimated hazard ratio for baseline CD4 counts is 0.180 (with a 
95% C.I. 0.084-0.388). Thus, patients their CD4 counts are above the threshold levels have 82% 
lower risk of death than those that are CD4 counts below the threshold levels. The confidence 
interval indicates that the risk of death for those patients that have CD4 counts above the 
threshold levels could be lower by a quantity as large as 38.8% or as low as 8.4% than patients 
that have CD4 counts below the threshold levels; p < 0.0001. 
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HIV-infected children aged below 1.5 years are 3.59 times more likely to die than children aged 
between 5 to 14 years (the reference category).  The 95% C.I. confirms that this hazard of death 
for this category could be as low as 1.439 and as high as 8.953 compared with the reference 
category. HIV-infected children aged between 1.55 and 5 years are 2.632 times more likely to 
die than children with age between 5 to 14 years (the reference category). The 95% CI verifies 
that the rate of death could be as small as 1.350 and as large as 5.130. HIV-infected children 
aged below 1.5 years are 1.36 times more likely to die than HIV-infected children aged between 
1.5 and 5 years given that all other factors are constant. 
The estimated risks of death for a patient with hemoglobin level less than 7gm/dl as compared to 
those patients with hemoglobin level greater than 10gm/dl (reference category) are 6.286(95% 
CI: 2.323, 16.973). This means that the hazard rate of death for hemoglobin level less than 
7gm/dl is 6.286 times more likely to die than HIV-infected children with hemoglobin level 
greater than 10gm/dl (reference category). And also, the estimated relative risk (hazard ratio) of 
dying for patients with hemoglobin level between 7-8.5gm/dl is 5.592 times more likely to die as 
compared to those patients with hemoglobin level greater than 10gm/dl (reference category). The 
95% C.I. suggests that the rate of death could be as small as 1.903and as large as 16.436. 
Moreover, the estimated hazard ratio of hemoglobin level between 8.5 to 10gm/dl compared to 
the reference hemoglobin level is 5.119 (95% CI: 1.579, 16.593). This implies that the risk dying 
for a patient with hemoglobin level between 8.5 to 10gm/dl is 5.119 more likely to die than those 
patients with hemoglobin level greater than 10gm/dl (reference category). Children with 
hemoglobin value less than 7gm/dl are 1.124 times more likely to die than children with 
hemoglobin value between 7gm/dl to 8.5gm/dl. Moreover, children with hemoglobin level 
greater than 10gm/dl are 84% less likely to die than children with hemoglobin value less than 
7gm/dl provided that all other factors are held constant. 
The reference category for the design variables of WHO clinical stage is patients who are in 
WHO clinical stage IV. The estimated hazard ratio for clinical stage III is 0.308 (with a 95% C.I. 
0.15-0.630). Thus, a patient whose clinical stage is III has approximately 0.308 times the hazard 
faced by patient whose clinical stage is IV (OR the hazard of death for clinical stage III are 70% 
less likely to die than those of clinical stage IV).  
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The 95% confidence interval indicates that the rate of dying for patients in clinical stage III is as 
high as 0.150 and as low as 0.630 that of patients in clinical stage IV. Similarly, the hazard ratio 
for clinical stage II is 0.151, which implies the rate of dying of patients in clinical stage (II) is 
0.151 times the rate of dying of patients in advanced clinical stage IV. The end points of the 95% 
CI also suggests that risk of death for patients in the clinical stage II is high as 51.3% and as low 
as 4.5%. Similarly, the hazard ratio for clinical stage I is 0.087, which implies the rate of dying 
of patients in clinical stage I is 91.3% less likely to die than patients in advanced clinical stage 
IV. The end points of the 95% CI confirm that risk of death for patients in the clinical stage I was 
as high as 37.3% and as low as 2%.  
On the other hand, the estimated hazard ratio of stage III compared to stage II and stage I was 
2.04 = 𝑒𝑥𝑝(−1.179 − (−1.890)) and 3.54 = 𝑒𝑥𝑝(−1.179 − (−2.443)), respectively. Since the 
confidence interval does not contain 1, an individual in clinical stage III has a significantly 
higher hazard rate than patients in clinical stage II & stage I. Thus, patients in stage III are 2.04 
times more likely to die than patients in stage II. Similarly the hazard rate of death for patients in 
WHO clinical stage III are 3.54 times more likely to die than patients in WHO clinical stage I.  
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4.8.2 Discussion of the Results 
This study identified variables/factors that are significantly associated with survival time of HIV-
infected children under ART treatments. Identifying patients at a higher risk of death has the 
advantage that due attention will be given to the risk group during their follow up to minimize 
the risk of mortality while they are taking ART. The above results suggested that the significant 
predictors of lower chance of survival in HIV-infected children after initiation of ART were: age 
less than 5 years, low CD4 count at baseline, advanced WHO clinical stage (stage III & IV) and 
low hemoglobin level are only significantly associated with survival time of HIV-infected 
children after initiation of ART in both the univariate and multivariate analysis. 
The results of this study show that the risk of death among HIV infected children for the age 
groups less than 1.5 years and 1.5 to 5 years are higher than those ages between 5 to 14 years. A 
study by Aregay et al. (30) identifies independent predictors of children’s mortality on ART. The 
result suggested that mortality of children on ART was low and factors that affect mortality of 
children on ART were age less than 18 months. A similar study by Mary Munyagwa et al. [26] 
also found that mortality among HIV-infected children was highest among those aged less than 2 
years. Thus, mortality among these high risk groups contributed to the higher rate of mortality. 
CD4 cell count is the most important marker of HIV disease progression and a strong predictor 
of survival HIV-infected children, similar to the plasma viral load. That may be due to the fact 
that HIV attacks CD4 cells, and as time goes by people with HIV often see their CD4 cell counts 
drop. That is the lower the CD4 cell count the greater the chances of getting a number of very 
serious diseases. The significant impact of CD4 cell count on survival rate has been revealed by 
many studies.  
A study in [25, 27 and 28] reported that patients with low baseline CD4 cell count were a strong 
risk factor for early mortality of HIV-infected children. Our results are also consistent with the 
findings in the above studies. But, a similar study conducted by Habtamu A. in Bahir-Dar were 
found that low baseline CD4 count was not predictor of survival time of HIV infected children 
[35]. His result contradicts with our findings that low baseline CD4 cell count were a strong risk 
factor for survival time of HIV infected children. 
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The finding of this study tells that observed higher risk of dying was found among HIV-infected 
children with lower hemoglobin level (anemic groups) compared to hemoglobin level greater 
than 10gm/dl, this study was consistent with other studies conducted elsewhere. According to 
Getachew et al. [31], it was found that hemoglobin level less than 7 gm/dl were significant 
independent predictors of death after controlling for other factors. For instance, another study 
also identifies that the determinants of mortality in Bahir-Dar showed that the risk death is higher 
among HIV-infected children with a lower hemoglobin level [35]. Therefore, the above studies 
confirm the same conclusion like our result.   
Like CD4 cell count, the WHO Clinical Staging system has been shown to be a practical and 
accurate way to manage HIV-infected patients. In this study, we found that the advanced WHO 
clinical stages III and IV were independent markers of mortality for patients on ART. The 
possible justification for the finding is that the advanced clinical stage of the disease is the cause 
for HIV-associated complications. A study in [27] was found that those children with WHO 
clinical stage IV had an increased risk of death. Similar to our finding, studies by [31, 32 and 35] 
provided evidence that children in advanced clinical stages (III and IV) had a strong association 
with high mortality of an HIV infected children on ART. 
The above sources showed that the most significant predictors of survival of children were CD4 
count, advanced WHO clinical stages, age, weight and to some extent opportunistic diseases like 
anemia and pneumonia. The findings of the current study identified advanced WHO clinical 
stage, age, hemoglobin level and baseline CD4 count as determinant predictors of survival of 
HIV-infected children treated with ART at Gondar University Hospital. Weight did not come out 
as a strong predictor although it is a clinically meaningful determining variable.  
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CHAPTER FIVE 
5. Conclusions and Recommendations  
5.1. Conclusions 
In this study, the survival/ death status of HIV-infected children who started ART treatment at 
Gondar university hospital between 2008 and 2013 and followed until April 2015 has been 
studied. It has utilized the data from the Gondar university hospital. In this paper we analyzed the 
child survival data using two approaches, that is the non-parametric (i.e. Keplan Meire and log-
rank test) and semi-parametric (Cox-regression analysis) techniques have been applied to 
identify the important predictors of child survival. 
In this study we tried to identify the factors that are associated with survival time of HIV infected 
children treated with ART in Gondar university hospital using the methods of survival analysis. 
The Kaplan-Meier and log-rank test are used to estimate and compare the survival time of 
children after initiation of ART treatment. The study has shown that the overall median survival 
time of HIV infected children under the study was 51.1 months. During the follow-up period out 
269 HIV infected children 46 (17.1%) of them experience the event (i.e. dead).  
 
Moreover, the results of the multivariable proportional hazards Cox regression model showed 
that CD4 count at the start of ART, age, advanced WHO clinical stages and low hemoglobin 
level (less than 7gm/dl and between 7 to 8.5gm/dl) are associated with higher risk of mortality. 
And also children whose age less than 1.5 years and age between 1.5 to 5 years and being in 
advanced WHO clinical stage III & IV are also associated with increased rate of mortality in 
both the univariable and multivariable analysis. Similarly, patients with poor health indicators 
like low baseline CD4 count and low hemoglobin level are less likely to survive. 
However, initial weight and baseline functional status are the two significant variables at 
univariable stage of analysis but not at multivariable analysis stage. Moreover, variables that are 
not significantly associated with survival time of HIV infected children after initiation of ART in 
both the univariable and multivariable analysis were gender, reasons for taking ART, 
Prophylaxis taken, baseline TB screen, opportunistic illness and the type of drug regimen used at 
the start of treatment.  
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Therefore, special attention should be given to younger children in ART; children should start 
ART treatment at early age, with CD4 count at the normal level or above the threshold level, 
when they have higher hemoglobin values and when they are at a lower clinical stage.  
5.2. Recommendations 
 Identifying patients at a higher risk of death has the advantage that due attention will be 
given to the risk group during their follow up to minimize the risk of mortality while they 
are taking ART. 
 Having lower CD4 count, lower hemoglobin levels and WHO clinical stage are indicators 
of the progression of the disease. Therefore, patients and care takers should be informed 
about the need for early diagnosis of HIV infection and starting treatment early is very 
important.  
 The high early mortality has to be addressed by increasing the availability of early HIV 
diagnosis and treatment services. 
 For further research work we would like to recommend that it was important to include 
virological variables in addition to clinical and socio-demographic variables. 
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APPENDIX 
Appendix: A 
 
Table 4.1: Distribution of important socio-demographic and Health factors of HIV infected 
children. 
Covariates  Category  Censored (%) Dead  Total  
Age age less than 1.5 years 
Ages between 1.5-5 years 
Ages between 5 - 14 years 
19(67.9%) 
75(78.1%) 
129(89.0%) 
19 
21 
16 
28 
96 
145 
Gender Male 
Female 
92(79.3%) 
131(85.6%) 
24 
22 
116 
153 
Baseline 
Functional Status 
Working 
Ambulatory 
Bedridden 
124(87.3%) 
58(85.3%) 
41(69.5%) 
18 
10 
18 
142 
68 
59 
Baseline WHO 
Stage 
Stage-1 
Stage-2 
Stage-3 
Stage-4 
44(95.7%) 
59(95.2%) 
72(86.7%) 
48(61.5%) 
2 
3 
11 
30 
46 
62 
83 
78 
Baseline CD4 
Count 
Above the threshold 
Below the threshold 
120(93.0%) 
103(73.6%) 
9 
37 
129 
140 
Original Regimen D4t-3TC-NVP 
D4t-3TC-EFV 
AZT-3TC-NVP 
AZT-3TC-EFV 
Other Drugs 
85(81.7%) 
8(72.7%) 
102(84.3%) 
9(75.0%) 
19(90.5%) 
19 
3 
19 
3 
2 
104 
11 
121 
12 
21 
Reason For ART Clinical 
CD4 
CD4 & Clinical 
CD4 & Lymphocytes 
20(87.0%) 
87(77.7%) 
80(90.9%) 
36(78.3%) 
3 
25 
8 
10 
23 
112 
88 
46 
Prophylaxis use no 
yes 
68(85.0%) 
155(82.0%) 
12 
34 
80 
189 
 
66 
 
Baseline 
TB Screen 
- ve 
+ve 
108(84.4%) 
115(81.6%) 
20 
26 
128 
141 
Opportunistic 
Illness 
no 
yes 
102(82.3%) 
121(83.4%) 
22 
24 
124 
145 
Base line  
Hemoglobin 
level(gm/dl) 
≤7.00 gm/dl 
7.00-8.50 gm/ dl 
8.50- 10.00 gm/dl 
> 10.00 gm/dl 
76(78.4%) 
30(73.2%) 
43(82.7%) 
74(93.7%) 
21 
11 
9 
5 
97 
41 
52 
79 
 
Table 4.2: Results of Kaplan-Meier survival times for children on antiretroviral treatment based 
on important clinical characteristics (categorical covariates). 
 
 
 
Covariates 
 
 
Category 
 
Mean
a 
 
 
Estimate 
 
Std. 
Error 
 
 
95% Confidence Interval 
 
 
Lower 
Bound 
 
Upper 
Bound 
Age age less than 1.5 years 
Ages between 1.5-5 years 
Ages between 5 - 14 years 
68.330 
72.832 
82.401 
5.888 
3.145 
2.026 
56.790 
66.668 
78.429 
79.871 
78.997 
86.373 
Gender Male 
Female 
74.589 
80.023 
2.812 
2.168 
69.077 
75.775 
80.100 
84.271 
Baseline 
Functional-
Status 
Working 
Ambulatory 
Bedridden 
79.642 
78.791 
68.711 
2.162 
3.298 
4.431 
75.601 
72.327 
60.027 
83.684 
85.255 
77.396 
Baseline 
WHO Stage 
stage 1 
stage 2 
stage 3 
stage 4 
86.774 
85.190 
81.096 
61.832 
2.239 
2.157 
2.784 
3.963 
82.386 
80.418 
75.639 
54.065 
91.163 
89.418 
86.553 
69.599 
Baseline 
CD4 Count 
Above the threshold 
Below the threshold 
85.184 
70.398 
1.561 
2.893 
82.125 
64.728 
88.242 
76.068 
Original 
Regimen 
D4t-3TC-NVP 
D4t-3TC-EFV 
AZT-3TC-NVP 
AZT-3TC-EFV 
other drugs 
77.592 
58.805 
78.710 
57.796 
64.810 
2.595 
8.949 
2.595 
6.059 
4.777 
72.505 
41.265 
73.625 
45.922 
55.447 
82.678 
76.345 
83.796 
69.671 
74.172 
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Reasons For 
ART 
Clinical 
CD4 
CD4 + Clinical 
CD4 + Lymhocyte 
63.348 
76.036 
81.907 
72.300 
4.132 
2.702 
2.405 
4.677 
55.249 
70.739 
77.193 
63.134 
71.446 
81.333 
86.621 
81.466 
Prophylaxis  
taken 
no 
yes 
77.817 
77.495 
2.978 
2.107 
71.979 
73.364 
83.654 
81.625 
Baseline TB 
Screen 
Ve 
+ve 
78.748 
76.349 
2.514 
2.431 
73.821 
71.585 
83.675 
81.113 
Opportunistic 
Illness 
No 
Yes 
76.656 
78.561 
2.769 
2.160 
71.229 
74.326 
82.083 
82.795 
Base line 
Hemoglobin 
Less or equal to 7.00 gm/dl 
7.00-8.50 gm/ dl 
8.50- 10.00 gm/dl 
More than 10.00 gm/dl 
72.085 
70.705 
76.521 
86.123 
3.097 
4.691 
4.046 
2.129 
66.015 
61.511 
68.591 
81.951 
78.155 
79.899 
84.451 
90.455 
 
 
Appendix: B 
Figure 4.2 (a-e): The plot of Kaplan-Meier estimate of survivor function of HIV infected 
children for age, functional status, WHO clinical stages, baseline CD4 counts and baseline 
hemoglobin levels can be presented as follows: 
a.                                                                             b. 
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c.                                                                        d.                         
                
                     e. 
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Table 4.5: Categorical Variable Coding’s for variables in the model 
Categorical Variable Codings
a,c,d,e,g
 
 Frequency (1)
f
 (2) (3) 
Age
b
 
.00=age less than 1.5 years 28 1 0  
1.00=Ages between 1.5-5 years 96 0 1  
2.00=Ages between 5 - 14 years 145 0 0  
BaselineFunctionalStat
us
b
 
0=Working 142 1 0  
1=Ambulatory 68 0 1  
2=Bedridden 59 0 0  
BaselineWHOStage
b
 
1=stage 1 46 1 0 0 
2=stage 2 62 0 1 0 
3=stage 3 83 0 0 1 
4=stage 4 78 0 0 0 
BaselineCD4Count
b
 
0=Above the threshold 129 1   
1=Below the threshold 140 0   
BaselineHemoglobin
b
 
0=Less or equal to 7.00 gm/dl 97 1 0 0 
1=7.00-8.50 gm/ dl 41 0 1 0 
2=8.50- 10.00 gm/dl 52 0 0 1 
3=More than 10.00 gm/dl 79 0 0 0 
a. Category variable: Age (age of patient ) 
b. Indicator Parameter Coding 
c. Category variable: BaselineFunctionalStatus (Baseline Functional Status) 
d. Category variable: BaselineWHOStage (Baseline WHO Clinical Stage) 
e. Category variable: BaselineCD4Count (Baseline CD4 Count) 
f. The (0,1) variable has been recoded, so its coefficients will not be the same as for indicator 
(0,1) coding. 
g. Category variable: BaselineHemoglobin (Base line Hemoglobin level) 
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Table 4.8: Results of the multiple Cox proportional hazards model which contain one interaction 
term at a time for Gondar University Hospital data of children ART. 
_t Haz. Ratio Std. Err. z P>z [95% Conf. Interval] 
age       
0 9.47e-09 2.28e-08 -7.69 0.000 8.54e-11 1.05e-06 
1 9.809603 12.09497 1.85 0.064 .8752729 109.9409 
stage       
1 2.11e-09 2.44e-09 -17.29 0.000 2.20e-10 2.03e-08 
2 1.127409 1.846174 0.07 0.942 .0455206 27.92257 
3 .2033978 .2895694 -1.12 0.263 .0124889 3.312593 
0.cd4 .3739598 .5673401 -0.65 0.517 .0191185 7.314683 
hemog       
0 11.69631 14.53521 1.98 0.048 1.023873 133.6139 
1 10.94703 14.2965 1.83 0.067 .8465478 141.5601 
2 22.72906 30.48782 2.33 0.020 1.63989 315.0273 
hemog*age       
0 0 4.46e+08 1.05e+09 8.46 0.000 4418099 4.50e+10 
0 1 .4043277 .5205045 -0.70 0.482 .0324305 5.040963 
1 0 1.55e+09 . . . . . 
1 1 .0905111 .1398028 -1.56 0.120 .0043847 1.868362 
2 0 1.85e+08 4.35e+08 8.08 0.000 1823466 1.87e+10 
2 1 .0842532 .1804087 -1.16 0.248 .0012675 5.600635 
hemog*stage       
0 1 3.08e-08 4.508585 -0.00 1.000 0 . 
0 2 .1547137 .2555369 -1.13 0.259 .006076 3.939466 
0 3 .7817974 1.015132 -0.19 0.850 .0613542 9.961952 
1 1 8.93e+08 . . . . . 
1 2 3.03e+18 1.05e+27 0.00 1.000 0 . 
1 3 1.403154 2.14482 0.22 0.825 .0701428 28.06901 
2 1 5.45e-09 .7103836 -0.00 1.000 0 . 
2 2 9.29e-18 1.16e-09 -0.00 1.000 0 . 
2 3 1.097714 1.703809 0.06 0.952 .0523966 22.99723 
hemog*cd4       
0 0 .3601698 .5110318 -0.72 0.472 .0223238 5.810936 
1 0 1.116929 1.667154 0.07 0.941 .0599105 20.82324 
2 0 .7688712 1.571306 -0.13 0.898 .0140053 42.20989 
cd4*age       
0 0 .0865048 .1601913 -1.32 0.186 .0022949 3.260707 
0 1 1.242605 1.387459 0.19 0.846 .1392852 11.08565 
cd4*stage       
0 1 1.84e-16 1.68e-08 -0.00 1.000 0 . 
0 2 1.67e-34 5.73e-26 -0.00 1.000 0 . 
0 3 1.198542 1.197297 0.18 0.856 .1691749 8.491234 
age*stage       
0 1 .0435178 .1229848 -1.11 0.267 .000171 11.07209 
0 2 8.37e+18 . . . . . 
0 3 11.78129 16.33447 1.78 0.075 .7780781 178.3869 
1 1 1.40e-17 1.82e-09 -0.00 1.000 0 . 
1 2 .3251663 .533609 -0.68 0.494 .0130393 8.108796 
1 3 1.466505 1.445077 0.39 0.698 .2125786 10.11691 
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Table 4.9: Results of the multivariable proportional hazards Cox regression model containing the 
variables in Table 4.7 and their interaction with log time (in months) 
 
 _t Haz. 
Ratio 
Std. Err. z P>z [95% 
Conf. 
Interval] 
main Age       
0 .7523224 .9430079 -0.23 0.820 .0644844 8.777143 
1 1.206992 .7967292 0.29 0.776 .3310019 4.401272 
Stage       
1 .1165201 .1912135 -1.31 0.190 .0046725 2.90571 
2 .1947696 .235671 -1.35 0.176 .0181789 2.086769 
3 .3420823 .2128175 -1.72 0.085 .1010597 1.157932 
0.cd4 .0816092 .1148786 -1.78 0.075 .0051705 1.288097 
Hemog       
0 3.586698 4.557836 1.01 0.315 .297181 43.28811 
1 3.828499 3.672349 1.40 0.162 .5841768 25.0907 
2 4.356039 3.187173 2.01 0.054 1.038234 18.2763 
tvc Age .7483167 .1621195 -1.34 0.181 .4894139 1.14418 
Stage 1.045118 .1881577 0.25 0.806 .7343771 1.487343 
cd4 .7970164 .3503386 -0.52 0.606 .3367526 1.886356 
Hemog .9321614 .1301795 -0.50 0.615 .7089538 1.225644 
Note: variables in tvc equation interacted with ln (_t) 
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Table 4.10: Test of proportional-hazards assumption 
Time:  Time    
 rho chi2 df Prob>chi2 
0.age 0.18343 1.83 1 0.1759 
1.age -0.03093 0.04 1 0.8361 
2b.age . . 1 . 
1.stage 0.24456 2.50 1 0.1138 
2.stage -0.15281 1.25 1 0.2638 
3.stage -0.10959 0.57 1 0.4522 
4b.stage . . 1 . 
0.cd4 0.10003 0.46 1 0.4984 
1b.cd4 . . 1 . 
0.hemog 0.05747 0.16 1 0.6908 
1.hemog 0.20365 1.94 1 0.1639 
2.hemog -0.00682 0.00 1 0.9626 
3b.hemog . . 1 . 
global test                  11.66                  9                           0.2335 
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Appendix: C 
Figure 4.4 (a-i): Graphs of the scaled Schoenfeld residuals and their Lowess smooth obtained 
from the model in Table 4.1 for the covariates CD4 count above the threshold, age <1.5 years, 
age between 1.5-5 years, clinical stage I, stage II and stage III. The line that passes through zero 
is a reference line. 
 
a.                                                                      b. 
                              
 
c.                                                                                                     d. 
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e.                                                                                                     f. 
                     
 
g.                                                                                                  h. 
                    
                                                  i. 
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Table 4.12: The five highest differences in the parameter estimates of the variables included in 
the model in Table 4.1 when the data value for each patient is in turn deleted from the model. 
 
Covariates Deleted observation’s (𝑖) ∆𝑗(−𝑖)= ?̂?𝑗 − 𝛽𝑗(−𝑖) |∆𝑗(−𝑖)= ?̂?𝑗 − 𝛽𝑗(−𝑖)| 
Age <1.5 25 
118 
225 
112 
101 
.1555451 
-.1221227 
.1207064 
.1174157 
-.1023482 
.1555451 
.1221227 
.1207064 
.1174157 
.1023482 
Age 1.5-5 years 18 
34 
111 
2 
250 
-.0822565 
-.076934 
-.0730739 
-.0650008 
-.0600498 
.0822565 
.076934 
.0730739 
.0650008 
.0600498 
Stage I 34 
112 
23 
250 
19 
.3315693 
.3286345 
-.0955252 
.081534 
-.0787862 
.3315693 
.3286345 
.0955252 
.081534 
.0787862 
Stage II 111 
15 
79 
84 
175 
.3024724 
.2815528 
.2640622 
-.1295603 
-.1054776 
.3024724 
.2815528 
.2640622 
.1295603 
.1054776 
Stage III 215 
134 
202 
130 
225 
.1041853 
.0949758 
.0893972 
.0892248 
.085573 
.1041853 
.0949758 
.0893972 
.0892248 
.085573 
CD4 above 77 .1316059 .1316059 
76 
 
threshold 195 
18 
31 
118 
.1207905 
.1195872 
.1181757 
.099334 
.1207905 
.1195872 
.1181757 
.099334 
HEMO 0 215 
255 
244 
15 
31 
-.2035968 
-.2004991 
-.2003334 
-.1973379 
-.1876917 
.2035968 
.2004991 
.2003334 
.1973379 
.1876917 
HEMO I 215 
244 
255 
31 
15 
-.2153348 
-.1994648 
-.1993998 
-.1926754 
-.1711015 
.2153348 
.1994648 
.1993998 
.1926754 
.1711015 
HEMO II 31 
255 
215 
244 
15 
-.1932776 
-.1879098 
-.1851313 
-.1841062 
-.1812352 
.1932776 
.1879098 
.1851313 
.1841062 
.1812352 
 
